

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

## The association between immune-inflammatory indexes and lower urinary tract symptoms: an analysis of cross-sectional data from the US National Health and Nutrition Examination Survey (2005–2008)

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-080826
Article Type:	Original research
Date Submitted by the Author:	12-Oct-2023
Complete List of Authors:	liu, wen; Chinese Academy of Medical Sciences & Peking Union Medical College, Wang, Jia; The Affiliated Hospital of Qingdao University, Department of Gastroenterology Wang, Miaomiao; Chinese Academy of Medical Sciences, Department of Urology; Chinese Academy of Medical Sciences Ding, Xin; Beijing Hospital, Department of Urology Wang, Miao; Chinese Academy of Medical Sciences, Department of Urology Liu, Ming; Chinese Academy of Medical Sciences, Department of Urology; Chinese Academy of Medical Sciences, Department of Urology;
Keywords:	Prostate, Prostate disease < UROLOGY, Kidney & urinary tract disorders < UROLOGY





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

	The association between immune-inflammatory indexes and lower urinary tract
2	symptoms: an analysis of cross-sectional data from the US National Health and
3	Nutrition Examination Survey (2005–2008)
4	Wen Liu <sup>1,2†</sup> , Jia Wang <sup>3†</sup> , Miaomiao Wang <sup>1,2</sup> , Xin Ding <sup>1</sup> , Miao Wang <sup>1*</sup> , and Ming Liu <sup>1,2*</sup>
5	1 Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric
6	Medicine, Chinese Academy of Medical Sciences, Beijing, China.
7	2 Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing,
8	China.
9	3 Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong,
10	China.
11	† Both authors contributed equally to this work
12	* Correspondence: Ming Liu, Department of Urology, Beijing Hospital, National Center of
13	Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No.1 DaHua
14	Road, Dong Dan, Beijing, 100730, China.
15	E-mail: liumingbjh@126.com
16	
17	Abstract
18	Objective This study aimed to systematically investigate the relationship between immune-
19	inflammatory indexes with lower urinary tract symptoms (LUTS).
20	Design Cross-sectional study.
21	Setting National Health and Nutrition Examination Survey (NHANES) (2005–2008).
22	Participants A total of 2,709 men with complete information for immune-inflammatory indexes and
23	LUTS were included from NHANES 2005–2008.
24	Outcomes and analyses Automated hematology analyzing devices are used to measure blood cell
25	counts, and LUTS were presented by standard questionnaires. Nonlinear and logistic regression
26	analysis were used to estimate their association after adjustment for confounders.
27	<b>Results</b> Multivariate logistic regression showed that PIV (OR[95%CI] = 1.60[1.14–2.23]), SIRI
28	(OR[95%CI] = 1.82[1.21-2.73]), NLR (OR[95%CI] = 1.81[1.31-2.49]), dNLR (OR[95%CI] = 1.81[1.31-2.49])
29	1.91[1.35-2.70]), and CRP (OR[95%CI] = 1.71[1.05-2.79]) was positively associated with LUTS.

#### **BMJ** Open

31	than any single index, with the ORs for high SIRI+high CRP, high NLR+high CRP, and high
32	dNLR+high CRP being 2.26, 2.44, and 2.16, respectively (All $P < 0.05$ ). Furthermore, subgroup
33	analyses revealed that age, smoking status, and hypertension have different effects on the relationship
34	between immune-inflammatory markers and LUTS.
35	Conclusions This study indicated that high levels of immune-inflammatory markers were associated
36	with an increased risk of clinical LUTS. The combination of CRP with SIRI, NLR, and dNLR
37	respectively showed a stronger positive correlation with clinical LUTS compared to any single index.
38	Keywords: NHANES; Lower urinary tract symptoms; prostatic hyperplasia; immune-inflammatory
39	index; inflammation
40	
41	STRENGTHS AND LIMITATIONS OF THIS STUDY
42	The NHANES dataset, representing the national population, enhances the generalizability of our
43	findings to a broader context.
44	This study investigates the positive correlation between various immune-inflammatory indexes
45	and lower urinary tract symptoms (LUTS).
46	Composite immune-inflammation markers exhibit a more robust association with LUTS compared
47	to individual indexes.
48	It's important to note that drawing causal conclusions from cross-sectional analyses presents
49	challenges.
50	Introduction
51	Introduction
52	Lower urinary tract symptoms (LUTS) are a common complaint among aging men, with
53	approximately 80% experiencing at least one urine symptom by the age of 80(1). LUTS is now widely
54	recognized as a term that encompasses various urinary symptoms, including storage, voiding,
55	postmicturition, and nocturia, negatively impacting on patients' quality of life(2, 3). In the United
56	States (US), nearly \$194 million is spent annually on LUTS drugs, which can impose a heavy strain on
57	the economy and public health(4, 5). Thus, it is essential to identify the factors that contribute to the
58	development and progression of LUTS in aging men.
59	Several inflammatory markers, including the pan-immune-inflammation value (PIV), systemic
60	inflammation response index (SIRI), systemic immune-inflammation index (SII),

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

neutrophil/lymphocyte ratio (NLR). derived neutrophil/lymphocyte ratio (dNLR), monocyte/lymphocyte ratio (MLR), platelet/lymphocyte ratio (PLR), and C-reactive protein (CRP), have been considered in the development and progression of inflammatory and infectious diseases(6-10). Interestingly, studies have also identified positive associations between inflammatory markers, such as CRP(10-12) and NLR(13, 14), and the risk of LUTS, suggesting that inflammation may play an important role in the development of LUTS. For instance, prostate tissue samples taken from individuals with benign prostatic hyperplasia (BPH), a condition often associated with LUTS resulting from bladder outlet obstruction, commonly exhibit acute and chronic inflammation(2, 15, 16). Additionally, inflammation may contribute to overactive bladder, which is another cause of LUTS(2, 17).

In recent years, a number of new inflammatory markers, such as PIV(18), SIRI(19), and SII(19), have been developed, yet no study has explored their relationship with LUTS. Furthermore, using these markers as single risk factors for LUTS could be limited by their low discriminatory power. Since the interplay between immunity, inflammation, and diseases involve complex networks, composite markers would be a more accurate and meaningful approach to capture the overall inflammatory status and reflect various immuno-inflammatory populations(20-22). Therefore, this study aims to systematically investigate the relationship between blood immune-inflammatory indexes and their combinations with LUTS, using representative NHANES data. This study sought to advance the understanding of the pathogenesis of LUTS and provide insights for potential interventions.

80 Methods

81 Study design and participants

The NHANES is a cross-sectional survey that employs a sophisticated multistage sample methodology to investigate the health and nutritional status of the non-institutionalized population in the US. The demographic information used in this study was obtained from the NHANES, and the protocol was approved by the National Center for Health Statistics Ethics Review Board. Written informed consent was obtained from all participants, and all NHANES data is publicly available on the relevant website(23).

In this study, we used publicly accessible data from two 2-year cycles of NHANES (2005-2006,
2007-2008) and restricted the analysis cohort to men aged 40 years or older. Initially, there were 3,506
man participants aged 40 years and older in our data. We excluded 417 participants with incomplete

#### **BMJ** Open

LUTS status and 150 participants with a history of prostate cancer. Additionally, 230 participants with
incomplete variables data were excluded. Finally, 2,709 participants were included in this study
(Supplementary Fig. 1).

## 94 Questionnaire Data Assessment

LUTS were assessed by four questions, including: (1) "Do you usually have trouble starting to urinate (pass water)?" (hesitancy, defined as the answer is yes); (2) "After urinating (passing water), does your bladder feel empty?" (incomplete emptying, defined as the answer is no); (3) "How often do you have urinary leakage?" (urinary frequency, defined as the answer is 1 or greater); (4) "During the past 30 days, how many times per night did you most typically get up to urinate, from the time you went to bed at night until the time you got up in the morning?" (nocturia, defined as an answer is 2 or greater). Daytime LUTS was defined as a participant with one or more of the first three symptoms listed above. Clinical LUTS was defined as a participant having two or more of the mentioned symptoms(1).

#### 104 Definition of Immune-Inflammation indexes

Automated hematology analyzing devices (Coulter DxH 800 analyzer) are used to measure lymphocyte, neutrophil, monocyte, and platelet count, which are presented as  $\times 10^{\$}3$  cells/ul. The Behring Nephelometer is used to measure serum CRP levels by latex-enhanced nephelometry, with a lower limit of detection (LLOD) of 0.2 mg/L. The immune-inflammatory indexes in our study were calculated as follows: PIV platelet neutrophil monocyte lymphocyte(18); SIRI = platelet × monocyte/lymphocyte(19); SII = platelet × neutrophil/lymphocyte(2) 4); NLR = neutrophil/lymphocyte(24); dNLR = neutrophil/(leukocyte-neutrophil)(25); MLR = monocyte/lymphocyte; PLR = platelet/lymphocyte(24).

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

113 Ascertainment of covariates

114 Our study considered several covariates that could potentially influence the association between 115 immune-inflammatory indexes and clinical LUTS, daytime LUTS, and nocturia. These covariates 116 included age, race, education level, smoking status, alcohol use, body mass index (BMI, kg/m<sup>2</sup>), blood 117 total cholesterol concentration, and history of hypertension and diabetes. Hypertension was defined as a 118 mean systolic blood pressure greater than 140 mmHg, or a mean diastolic blood pressure less than 90 119 mmHg, or a self-reported history of hypertension. Diabetes was defined as the use of antidiabetic 120 treatment, an HbA1c level of  $\geq 6.5\%$ , or a self-reported history of diabetes.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

### 

## 121 Statistical analysis

To obtain nationally representative findings for the men population aged 40 and over in the US, survey weights were included in the analysis in accordance with NHANES standards. Baseline feature indicators were presented as weighted mean and standard error (SE) for continuous data and weighted ratio for classified data. The difference between baseline characteristics was assessed using the student's t-test on continuous data and the Chi-square test on classified data. We used restricted cubic splines with three nodes at the 5th, 50th, and 95th percentiles to evaluate the nonlinear correlation between immune-inflammatory indexes and clinical LUTS, daytime LUTS and nocturia. Multivariate logistic regression was utilized in three models to explore the association between immune-inflammatory indexes and clinical LUTS, daytime LUTS and nocturia. Covariates were not adjusted in model 1, age, race, education level, smoking status, alcohol use, and BMI were adjusted in model 2, and model 3 was further adjusted for blood total cholesterol, and a history of diabetes and hypertension. Additionally, we conducted multivariate logistic ordinal regression analyses to verify the association of immune-inflammatory indexes with the number of positive symptoms associated with clinical LUTS (0, 1, 2, 3, 4). Furthermore, multiple logistics regression was used to explore whether there is a stronger correlation between SIRI + CRP, NLR + CRP, dNLR + CRP and clinical LUTS. Subgroup analyses were performed for the association between immune-inflammatory indexes and clinical LUTS, stratified by age, smoking, and a history of hypertension, and multiplicative interaction terms were used to test for interactions.

All statistical analyses were performed using R (version 4.2.2, http://www.r-project.org/).
Statistical significance was defined as a two-sided *P*-value < 0.05.</li>

142 Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting, ordissemination plans of this research.

145 Results

#### 146 Baseline characteristics

As shown in Table 1, we included 2709 men participants aged 40 and above with complete information, including 399 men who met the diagnostic criteria of clinical LUTS, 675 men who met the diagnostic criteria of daytime LUTS, and 946 men who had nocturia symptoms. Compared to men without clinical LUTS, men with clinical LUTS were older, less educated, smokers, and non-alcohol

#### **BMJ** Open

users, more prone to have lower blood cholesterol concentration, and higher hypertension, diabetes, PIV, SIRI, SII, NLR, dNLR and MLR values (all P < 0.05). Similarly, compared to men without daytime LUTS, men with daytime LUTS were older, non-alcohol users, more likely to have hypertension, diabetes, and higher PIV, SIRI, NLR, dNLR and MLR values (all P < 0.05). Furthermore, compared to men without nocturia, men with nocturia were found to be older, non-Hispanic Black, less educated, smokers, and non-alcohol users, more prone to have lower blood cholesterol concentration, and higher BMI, hypertension, diabetes, PIV, SIRI, NLR and MLR values (all P < 0.05).

#### Dose-response relationships between immune-inflammatory indexes and LUTS

We used restricted cubic splines to assess the non-linear correlation between immune-inflammatory indexes and LUTS. After adjusting for covariates, we found that PIV, SIRI, SII, NLR, dNLR, MLR, and CRP had a linear relationship with clinical LUTS, daytime LUTS, and nocturia (all P for non-linearity > 0.05). Specifically, the prevalence of clinical LUTS increased by 14%, 22%, 16%, 24%, 21% and 21% per standard deviation of PIV, SIRI, SII, NLR, dNLR and CRP, respectively (all P < 0.05) (Fig. 1). The prevalence of daytime LUTS increased by 15%, 23%, 20%, and 15% per standard deviation of SIRI, NLR, dNLR and CRP, respectively (all P < 0.05) (Supplementary Fig. 2). The prevalence of nocturia increased by 15%, 12%, 19%, and 23% per standard deviation of SIRI, NLR, MLR and CRP, respectively (all P < 0.05) (Supplementary Fig. 3).

#### 

## Multivariate logistic regression analyses between immune-inflammatory indexes and LUTS

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

To further clarify the relationship between immune-inflammatory indexes and LUTS, we classified each index into quartiles (Q1, Q2, Q3, Q4) and performed multiple logistic regression analyses with the O1 group as reference. Our results showed that O4 groups of PIV, SIRI, NLR, dNLR, and CRP were positively correlated with clinical LUTS in all three models (all P < 0.05, all P for trend < 0.05). After adjustment for all confounders, PIV (OR = 1.60, 95% CI = 1.14-2.23), SIRI (OR = 1.82, 95%*CI* = 1.21–2.73), NLR (*OR* = 1.81, 95%*CI* = 1.31–2.49), dNLR (*OR* = 1.91, 95%*CI* = 1.35–2.70), and CRP (OR = 1.71, 95%CI = 1.05-2.79) in the Q4 group were significant risk factors for clinical LUTS in model 2. In the crude model, we also found that SII (OR = 1.45, 95% CI = 1.02-2.06) and MLR (OR = 1.96, 95% CI = 1.17 - 3.28) in the Q4 group were positively correlated with LUTS (Table 2). Furthermore, to confirm the linear relationship between these immune-inflammatory indexes and LUTS, we conducted a multiple ordinal logistic regression analysis and found a significant positive

181 correlation between SIRI, SII, NLR, dNLR, MLR, and CRP and the number of positive symptoms182 associated with clinical LUTS (Supplementary table 1).

Regarding the presence of daytime LUTS, we found a significant association between NLR (Q4, OR = 1.82, 95%CI = 1.21-2.74, dNLR (Q4, OR = 1.81, 95%CI = 1.20-2.71), and SIRI (Q4, OR = 1.81, 95%CI = 1.20-2.71), and SIRI (Q4, OR = 1.81, 95%CI = 1.20-2.71), and SIRI (Q4, OR = 1.81, 95%CI = 1.20-2.71), and SIRI (Q4, OR = 1.81, 95\%CI = 1.80, 95\% 1.82, 95%CI = 1.05-3.17) and increased risk of daytime LUTS (Supplementary table 2). In contrast, in the outcome of nocturia, MLR (Q4, OR = 1.49, 95%CI = 1.07–2.08) and CRP (Q4, OR = 1.59, 95%CI = 1.08-2.34) were significantly associated with nocturia (Supplementary table 3). Given the varying associations between immune-inflammatory indexes and different LUTS characteristics, we combined different indexes based on the results in Table 2. We selected cut-off values of 1.14, 2.08, 1.84, and 0.43 for SIRI, NLR, dNLR, and CRP, respectively, and divided them into high and low-level groups. We then combined SIRI, NLR, and dNLR with CRP in pairs to explore the correlation between the combined markers and clinical LUTS. The reference groups were the low CRP + low SIRI, low CRP + low NLR, and low CRP + low dNLR groups. As expected, when combined in pairs, the markers showed a stronger association with clinical LUTS than any single index alone, with the ORs for high SIRI + high CRP, high NLR + high CRP, and high dNLR + high CRP being 2.26 (95%CI = 1.56-3.26), 2.44 (95%CI = 1.60-3.71), and 2.16 (95%CI = 1.21-3.87), respectively, and there was a significant increasing trend for the prevalence of clinical LUTS (all P < 0.05) (Table 3).

## 198 Subgroup analyses

In our subgroup analyses, we examined the impact of age, smoking, and hypertension on the relationship between immune-inflammatory indexes and LUTS (Fig. 2). Using the Q1 group as a reference, we found a more pronounced positive association between PIV, SIRI, SII, NLR, dNLR, MLR, CRP and clinical LUTS in older men aged 60 years and older in the Q4 group compared to those under 60 years (all P < 0.05, all P for interaction < 0.05). Similarly, smokers exhibited a stronger positive correlation between PIV, SIRI, NLR, CRP and clinical LUTS in the Q4 group than non-smokers (all P < 0.05, all P for interaction < 0.05). Additionally, hypertensive men in the Q4 group showed a significantly positive association between SIRI, NLR, dNLR and clinical LUTS than those without a history of hypertension (all P < 0.05, all P for interaction < 0.05). These findings suggested that age, smoking, and hypertension might modify the impact of immune-inflammatory status on clinical LUTS, and should be taken into consideration in clinical practice.

210 Discussion

#### **BMJ** Open

This study represents the first attempt to systematically investigate the association between different immune-inflammatory markers and LUTS risk, and to explore the potential effects of combining them. These findings revealed strong positive linear correlations between PIV, SIRI, NLR, dNLR, and CRP with clinical LUTS. Interestingly, when CRP was combined with SIRI, NLR, and dNLR respectively, the positive correlations with clinical LUTS became even stronger compared to any of the individual indexes alone. Additionally, subgroup analysis found that the effects of age, smoking, and history of hypertension varied in their influence on the relationship between immune-inflammatory indexes and clinical LUTS.

Previous studies have investigated the mechanisms underlying the association between inflammation and LUTS. As a common disease in aging men that can contribute to LUTS, the development and progression of BPH are closely related to prostatic inflammation(2, 3). In fact, Theyer et al. reported that human BPH tissue had a substantial influx of activated T cells, which secret various growth factors that facilitate prostate stromal and glandular hyperplasia(26). Additionally, stromal cells in BPH patients can stimulate the production of proinflammatory cytokines and chemotherapeutic kinases in a state of inflammation(27), such as IL-2, IL-4, IL-7, IL-17, and IFNy(28-30). Moreover, chronic inflammation in BPH is linked to the focal overexpression of cyclooxygenase 2 in the glandular epithelium, which results in the production of proinflammatory prostaglandins and prostate cell proliferation(27, 31). Furthermore, the pathogenesis of LUTS may involve different types of bladder dysfunction, such as detrusor overactivity or underactivity(2). There is a possible connection between inflammation and overactive bladder, which could be due to inflammation-induced remodeling of extracellular matrix and an increase in tissue stiffness(3). All the above studies have shown that there is a certain relationship between immune inflammation and LUTS.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

The risk of LUTS has been found to be associated with immune-inflammation indexes, which are readily available and inexpensive biomarkers. Although Rohrmann et al. did not find a positive correlation between CRP and LUTS using NHANESIII data(32), several studies revealed that an elevated level of CRP was related to an increased risk of LUTS(10-12, 33), consistent with our findings. The discrepancy in results may be due to differences in CRP classification criteria. Additionally, previous small-scale studies have identified a link between elevated NLR levels and the progression of LUTS/BPH without performing multivariable analysis(13, 14). In contrast, our study provides strong evidence for a significant relationship between NLR and the prevalence of LUTS,

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

regardless of whether NLR was treated as a continuous or categorical variable in multivariable regression analysis. Specially, we found that elevated levels of CPR were primarily associated with nocturia, while NLR, dNLR, and SIRI were associated with daytime LUTS. Given that previous studies have combined inflammatory markers to better reflect their relationship with disease(20-22), we attempted to combine CRP with NLR, dNLR, and SIRI. Our findings highlight a stronger linear correlation between the combination of these indexes and the risk of LUTS, indicating that composite immune-inflammation markers may be more effective in reflecting the risk of LUTS.

In our study, we discovered for the first time that several immune-inflammation biomarkers, namely PIV, SIRI, and dNLR, were positively correlated with the presence of clinical LUTS. Among these biomarkers, PIV stands out for its comprehensive nature, as it comprises peripheral blood counts of neutrophils, monocytes, lymphocytes, and platelets(18), making it a promising prognostic biomarker for various cancers(34). Similarly, SIRI and SII have been established as a prognostic indicator for different types of tumors(35-37) and inflammation-related diseases(38-40), as they reflect the balance between the immune response and inflammation. After adjusting for covariates, we found that SIRI was positively associated with LUTS while SII was not, which might be due to the weak relationship between platelets and LUTS. Among these pro-inflammatory cells, NLR has been the most extensively validated. However, dNLR, which replaces the denominator of NLR with (WBC-neutrophils), has emerged as an alternative in cases where lymphocyte information is unavailable(41). Proctor et al. found that both NLR and dNLR have equal reliability for the prognostic value in patients with cancer(41). Our study revealed a significant correlation between NLR and the prevalence of LUTS, as well as a comparable association between dNLR and LUTS. Since both indexes include neutrophils, it emphasizes the strong and intimate link between neutrophils and LUTS, relative to other pro-inflammatory cells.

Subgroup analyses revealed that the positive association between inflammation and clinical LUTS was stronger among the elderly, smokers, and hypertensive patients, highlighting the potential role of excessive production and release of inflammatory factors in these populations, leading to increased levels of inflammation(42-44). Additionally, factors such as physical aging, smoking, and hypertension may contribute to a higher prevalence of LUTS through mechanisms such as prostate and bladder aging, impaired renal function, and damage to blood vessels and nerves(45-47). Thus, it is important to closely monitor the inflammation levels in these populations suffering from LUTS, and providing anti-

inflammatory interventions for those with high inflammation levels might be a promising treatmentoption.

This study has several advantages. Firstly, this is the first study to systematically explore the relationship between immune-inflammation indexes and LUTS, emphasizing the importance of monitoring inflammation levels in individuals with LUTS. Secondly, the NHANES dataset comprises a representative sample of the national population, and we utilize NHANES-provided weights to ensure that our findings can be extrapolated to the broader population. Furthermore, multiple potential confounders were adjusted to ensure reliable results. However, this study also has several limitations. Firstly, peripheral blood was tested only once rather than repeatedly, which may not accurately reflect a person's long-term peripheral blood status. Secondly, the questionnaire survey may have been subject to recall bias and reporting bias. Finally, it is difficult to draw causal conclusions from such cross-sectional analyses.

#### 283 Conclusions

In conclusion, this study emphasized that high levels of immune-inflammatory indexes such as PIV, SIRI, NLR, dNLR, and CRP were independent risk factors for clinical LUTS. The combination of CRP with SIRI, NLR, and dNLR respectively showed a stronger positive correlation with clinical LUTS compared to any of the individual indexes alone. Furthermore, the impact of age, smoking, and history of hypertension on the relationship between immune-inflammatory indexes and LUTS was significant. Further research, including multi-center studies, is needed to confirm the relationship between immune-inflammatory indexes and LUTS and to provide additional evidence for the management and treatment of clinical LUTS.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### 293 Acknowledgments

We appreciate the American Centers for Disease Control and Prevention for conducting the survey andmaking it available online freely, and all the participants for providing these data.

296 Contributors

W-L: conceptualization, methodology, data analysis, manuscript writing; J-W: methodology, data
collection, data analysis, manuscript writing; MM-W: methodology, data collection, data analysis; MW: data analysis, manuscript writing; X-D: methodology, supervision; M-L: conceptualization,
supervision, manuscript editing, funding acquisition.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16 17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42 43	
43 44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

301	Funding
302	This work was supported by the National Key Research and Development Program of China
303	[2022YFC3602900] and Innovation Funds for Postgraduates of Peking Union Medical College [2021-
304	I2M-1-050].
305	Competing interests
306	None declared
307	Patient consent for publication
308	Not applicable.
309	Ethical statement
310	Ethical review and approval for the research involving human participants were obtained from the
311	Ethics Review Board of the NCHS (Protocol #98-12). The current analysis, which is based on publicly
312	available data, did not necessitate any further ethics approval. Written informed consent was obtained
313	from all patients or participants who were part of the study.
314	Data availability statement
315	Publicly available datasets were analyzed in this study. This data can be downloaded here:
316	https://www.cdc.gov/nchs/nhanes/ (NHANES 2005-2006 and 2007-2008).
317 318	Deference
	Reference
319	1. Fantus RJ, Packiam VT, Wang CH, Erickson BA, Helfand BT. The Relationship between
320	Sleep Disorders and Lower Urinary Tract Symptoms: Results from the NHANES. J Urol.
321	2018;200(1):161-6.
322	2. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et
323	al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract
324	Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015;67(6):1099-109.
325	3. He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, Gupta S. Metabolic syndrome,
326	inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer
327	Prostatic Dis. 2016;19(1):7-13.

**BMJ** Open

Bavendam TG, Norton JM, Kirkali Z, Mullins C, Kusek JW, Star RA, et al. Advancing a Comprehensive Approach to the Study of Lower Urinary Tract Symptoms. J Urol. 2016;196(5):1342-9. Welliver C, Feinstein L, Ward JB, Fwu CW, Kirkali Z, Bavendam T, et al. Trends in Lower 5. Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project. J Urol. 2020;203(1):171-8. Cakir U, Tayman C, Tugcu AU, Yildiz D. Role of Systemic Inflammatory Indices in the Prediction of Moderate to Severe Bronchopulmonary Dysplasia in Preterm Infants. Arch Bronconeumol. 2023. Cakir U, Tugcu AU, Tayman C, Yildiz D. Evaluation of the effectiveness of systemic 7. inflammatory indices in the diagnosis of respiratory distress syndrome in preterm with gestational age of ≤32 weeks. Am J Perinatol. 2023. 8. Wang RH, Wen WX, Jiang ZP, Du ZP, Ma ZH, Lu AL, et al. The clinical value of neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR) and systemic inflammation response index (SIRI) for predicting the occurrence and severity of pneumonia in patients with intracerebral hemorrhage. Front Immunol. 2023;14:1115031. Erdogan A, Can FE, Gönüllü H. Evaluation of the prognostic role of NLR, LMR, PLR, and 9. LCR ratio in COVID-19 patients. J Med Virol. 2021;93(9):5555-9. 10. Kim JH, Doo SW, Yang WJ, Song YS, Kwon SS. Association Between High-sensitivity C-reactive Protein and Lower Urinary Tract Symptoms in Healthy Korean Populations.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

349 Urology. 2015;86(1):139-44.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### **BMJ** Open

11. St Sauver JL, Sarma AV, Jacobson DJ, McGree ME, Lieber MM, Girman CJ, et al. Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol. 2009;169(11):1281-90. 12. Lu Z, Gao Y, Tan A, Yang X, Zhang H, Mo L, et al. Increased high-sensitivity C-reactive protein predicts a high risk of lower urinary tract symptoms in Chinese male: Results from the Fangchenggang Area Male Health and Examination Survey. Prostate. 2012;72(2):193-200. 13. Ozer K, Horsanali MO, Gorgel SN, Horsanali BO, Ozbek E. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome. Urol Int. 2017;98(4):466-71. 14. Tanik S, Albayrak S, Zengin K, Borekci H, Bakirtas H, Imamoglu MA, et al. Is the neutrophil-lymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia? Asian Pac J Cancer Prev. 2014;15(15):6375-9. 15. Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management. J Urol. 2021;206(4):806-17. 16. Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, et al. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016;2:16031. 17. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49. 18. Fucà G, Guarini V, Antoniotti C, Morano F, Moretto R, Corallo S, et al. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results

## BMJ Open

2		
3 4 5	372	from a pooled-analysis of the Valentino and TRIBE first-line trials. Br J Cancer.
6 7 8	373	2020;123(3):403-9.
9 10	374	19. Jin Z, Wu Q, Chen S, Gao J, Li X, Zhang X, et al. The Associations of Two Novel
11 12 13	375	Inflammation Indexes, SII and SIRI with the Risks for Cardiovascular Diseases and All-Cause
14 15	376	Mortality: A Ten-Year Follow-Up Study in 85,154 Individuals. J Inflamm Res. 2021;14:131-40.
16 17 18	377	20. Abbate V, Barone S, Troise S, Laface C, Bonavolontà P, Pacella D, et al. The
19 20 21	378	Combination of Inflammatory Biomarkers as Prognostic Indicator in Salivary Gland
22 23	379	Malignancy. Cancers (Basel). 2022;14(23).
24 25 26	380	21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory
27 28 29	381	biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama.
30 31	382	2013;309(22):2353-61.
32 33 34	383	22. Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic
35 36	384	Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic
37 38 39	385	Marker of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. Front Oncol.
40 41 42	386	2019;9:914.
42 43 44	387	23. National Health and Nutrition Examination Survey. Available from:
45 46 47	388	https://www.cdc.gov/nchs/nhanes/ [Accessed March 23, 2023 pp.].
48 49	389	24. Ruan GT, Xie HL, Zhang HY, Zhang Q, Deng L, Wang ZW, et al. Association of systemic
50 51 52	390	inflammation and low performance status with reduced survival outcome in older adults with
53 54 55	391	cancer. Clin Nutr. 2022;41(10):2284-94.
56 57	392	25. Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of
58 59 60	393	the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients

Page 16 of 34

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

394	With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018;4(3):351-7.
395	26. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, et al.
396	Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab
397	Invest. 1992;66(1):96-107.
398	27. Chughtai B, Lee R, Te A, Kaplan S. Inflammation and benign prostatic hyperplasia:
399	clinical implications. Curr Urol Rep. 2011;12(4):274-7.
400	28. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an
401	immune inflammatory disease? Eur Urol. 2007;51(5):1202-16.
402	29. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, et al. Increased
403	expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue,
404	identification of the producing cell types, and effect of differentially expressed cytokines on
405	stromal cell proliferation. Prostate. 2002;52(1):43-58.
406	30. Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, Reithmayr F, et al. Cytokine
406 407	30. Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, Reithmayr F, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic
	La
407	expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic
407 408	expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest. 2003;83(8):1131-46.
407 408 409	expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest. 2003;83(8):1131-46. 31. Kaplan SA. Chronic Inflammation in Benign Prostate Hyperplasia is Associated With
407 408 409 410	expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest. 2003;83(8):1131-46. 31. Kaplan SA. Chronic Inflammation in Benign Prostate Hyperplasia is Associated With Focal Upregulation of Cyclooxygenase-2, Bcl-2, and Cell Proliferation in the Glandular
407 408 409 410 411	expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest. 2003;83(8):1131-46. 31. Kaplan SA. Chronic Inflammation in Benign Prostate Hyperplasia is Associated With Focal Upregulation of Cyclooxygenase-2, Bcl-2, and Cell Proliferation in the Glandular Epithelium. J Urol. 2005;173(4):1266-7.
407 408 409 410 411 412	<ul> <li>expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest. 2003;83(8):1131-46.</li> <li>31. Kaplan SA. Chronic Inflammation in Benign Prostate Hyperplasia is Associated With Focal Upregulation of Cyclooxygenase-2, Bcl-2, and Cell Proliferation in the Glandular Epithelium. J Urol. 2005;173(4):1266-7.</li> <li>32. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein</li> </ul>
407 408 409 410 411 412 413	expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest. 2003;83(8):1131-46. 31. Kaplan SA. Chronic Inflammation in Benign Prostate Hyperplasia is Associated With Focal Upregulation of Cyclooxygenase-2, Bcl-2, and Cell Proliferation in the Glandular Epithelium. J Urol. 2005;173(4):1266-7. 32. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and

**BMJ** Open

416 with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia.

417 PLoS One. 2014;9(1):e85588.

418 34. Guven DC, Sahin TK, Erul E, Kilickap S, Gambichler T, Aksoy S. The Association
419 between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review
420 and Meta-Analysis. Cancers (Basel). 2022;14(11).

- 421 35. Meng L, Yang Y, Hu X, Zhang R, Li X. Prognostic value of the pretreatment systemic 422 immune-inflammation index in patients with prostate cancer: a systematic review and meta-
  - 423 analysis. J Transl Med. 2023;21(1):79.

424 36. Cao Y, Zheng X, Hu Y, Li J, Huang B, Zhao N, et al. Levels of systemic inflammation
425 response index are correlated with tumor-associated bacteria in colorectal cancer. Cell Death
426 Dis. 2023;14(1):69.

427 37. Zhang S, Du J, Zhong X, Tan P, Xu H, Zhang J, et al. The prognostic value of the 428 systemic immune-inflammation index for patients with bladder cancer after radical cystectomy. Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

429 Front Immunol. 2022;13:1072433.

430 38. Biyik M, Biyik Z, Asil M, Keskin M. Systemic Inflammation Response Index and Systemic
431 Immune Inflammation Index Are Associated with Clinical Outcomes in Patients with Acute
432 Pancreatitis? J Invest Surg. 2022;35(8):1613-20.

433 39. Huang YW, Yin XS, Li ZP. Association of the systemic immune-inflammation index (SII)

434 and clinical outcomes in patients with stroke: A systematic review and meta-analysis. Front

435 Immunol. 2022;13:1090305.

436 40. Song Y, Guo W, Li Z, Guo D, Li Z, Li Y. Systemic immune-inflammation index is 437 associated with hepatic steatosis: Evidence from NHANES 2015-2018. Front Immunol.

438	2022;13:1058779.
439	41. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived
440	neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer.
441	2012;107(4):695-9.
442	42. Liberale L, Badimon L, Montecucco F, Lüscher TF, Libby P, Camici GG. Inflammation,
443	Aging, and Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol.
444	2022;79(8):837-47.
445	43. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular
446	disease: an update. J Am Coll Cardiol. 2004;43(10):1731-7.
447	44. Mouton AJ, Li X, Hall ME, Hall JE. Obesity, Hypertension, and Cardiac Dysfunction:
448	Novel Roles of Immunometabolism in Macrophage Activation and Inflammation. Circ Res.
449	2020;126(6):789-806.
450	45. Kim EH, Larson JA, Andriole GL. Management of Benign Prostatic Hyperplasia. Annu
451	Rev Med. 2016;67:137-51.
452	46. Matzkin H, Soloway MS. Cigarette smoking: a review of possible associations with
453	benign prostatic hyperplasia and prostate cancer. Prostate. 1993;22(4):277-90.
454	47. Gacci M, Corona G, Sebastianelli A, Serni S, De Nunzio C, Maggi M, et al. Male Lower
455	Urinary Tract Symptoms and Cardiovascular Events: A Systematic Review and Meta-analysis.
456	Eur Urol. 2016;70(5):788-96.
457 458 459 460 461 462	<b>Figure legend</b> <b>Fig. 1</b> Dose-response relationships between blood immune-inflammatory indexes and clinical LUTS (A) PIV and clinical LUTS; (B) SIRI and LUTS; (C) SII and LUTS; (D) NLR and LUTS; (E) dNLR and LUTS; (F) MLR and LUTS; (G) PLR and LUTS; (H) CRP and LUTS. They are adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI, total cholesterol, and a history of

#### **BMJ** Open

diabetes and hypertension. The shaded part represents the 95% CI. Abbreviations: OR, odds ratio;
LUTS, lower urinary tract symptoms; PIV, pan-immune-inflammation value; SIRI, system
inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to
lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio;
PLR, platelet to lymphocyte ratio; CRP, C-reactive protein.

Fig. 2 Associations between blood immune-inflammatory indexes and clinical LUTS in subgroup
analyses. They are adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and
BMI, total cholesterol, and a history of diabetes and hypertension, if not already stratified.
Abbreviations: OR, odds ratio; LUTS, lower urinary tract symptoms; PIV, pan-immune-inflammation
value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR,
neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to
lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein.

477 Supplementary Fig. 1 Study flowchart. Of 20,497 participants in the 2005–2008 National Health and
478 Nutrition Examination Survey (NHANES), 2,709 remained after fulfilling inclusion and exclusion
479 criteria

Supplementary Fig. 2 Dose-response relationships between blood immune-inflammatory indexes and daytime LUTS (A) PIV and LUTS; (B) SIRI and LUTS; (C) SII and LUTS; (D) NLR and LUTS; (E) dNLR and LUTS; (F) MLR and LUTS; (G) PLR and LUTS; (H) CRP and LUTS. They are adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI, total cholesterol, and a history of diabetes and hypertension. The shaded part represents the 95% CI. Abbreviations: OR, odds ratio; LUTS, lower urinary tract symptoms; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Supplementary Fig. 3 Dose-response relationships between blood immune-inflammatory indexes and nocturia (A) PIV and LUTS; (B) SIRI and LUTS; (C) SII and LUTS; (D) NLR and LUTS; (E) dNLR and LUTS; (F) MLR and LUTS; (G) PLR and LUTS; (H) CRP and LUTS. They are adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI, total cholesterol, and a history of diabetes and hypertension. The shaded part represents the 95% CI. Abbreviations: OR, odds ratio; LUTS, lower urinary tract symptoms; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein.

 Table 1. Demographic and clinic characteristics according to clinical LUTS, daytime LUTS, and nocturia. NHANES 2005-2008\*

	Total	Clinica	I LUTS		Daytim	e LUTS		Noct	turia	
Characterist ics	Adults (N = 2709)	No (N = 2310)	Yes (N = 399)	P value	No (N = 2034)	Yes (N = 675)	P value	No (N = 1763)	Yes (N = 946)	– P value
Age, years,		,		<	· · · · · ·		<		^	<
n (%)				0.01			0.01			0.01

≥ 60       10         Race/ethnici       ty, n (%)         Non-       15         Hispanic       06         Non-       50         Hispanic       9         Mexican       )         Mexican       )         Other       260         Particle       9         Grades 0–12       82         Other       0)         High school       graduate/GE         graduate/GE       10         Some college       12         or above       59         Smoking <sup>†</sup> , n       (%)         Yes       16         Yes       16         No       10         Some college       12         or above       59         Smoking <sup>†</sup> , n       (%)         Yes       16         Yes       17         No       10         BMI <sup>§</sup> ,       kg/m², n (%)         < 25       31         25–29.9       11	) 02(78. ) 8(8.82 3(6.14 6(6.99 1(17.8 1(25.6 37(56. ) 81(59. ) 28(40. ) 76(72. ) 3(27.3	1070(32. 10) 1261(77. 96) 435(8.90) 379(6.19) 235(6.96) ) 675(16.7 3) 555(25.5 3) 1080(57. 74) 1390(57. 37) 920(42.6 3) 1550(74. 51) 2(0) 5.4	277(56.5 + 4) $241(78.7 + 7)$ $73(8.22)$ $54(5.81)$ $31(7.20)$ $146(25.6 + 3)$ $96(26.19 + 3)$ $157(48.1 + 8)$ $291(72.9 + 9)$ $108(27.0 + 1)$ $226(59.4 + 1)$	0.94 < 0.01 < 0.01	924(31.4 0) 1108(77. 87) 388(9.15 ) 334(6.24 ) 204(6.75 ) 599(16.8 5) 487(25.2 2) 948(57.9 4) 1227(58. 41) 807(41.5 9)	423(47.9 1) 394(78.7 1) 120(7.66 ) 99(5.81) 62(7.83) 222(21.1 0) 164(26.9 8) 289(51.9 1) 454(62.1 8) 221(37.8 2)	0.67 0.08 0.06	718(27.8 3) 1003(80. 02) 298(7.34 ) 272(5.46 ) 190(7.18 ) 460(14.5 0) 433(25.7 5) 870(59.7 5) 1036(55. 58) 727(44.4 2)	629(55.1 2) 499(72.6 3) 210(12.8 8) 161(8.03) 76(6.46) 361(26.8 9) 218(25.2 3) 367(47.8 8) 645(69.3 7) 301(30.6 3)	< 0.01 < 0.01 < 0.01
Race/ethnici       ty, n (%)         Non-       15         Hispanic       06         Non-       50         Hispanic       90         Mexican       3         Other       26         Dother       9         Grades 0–12       82         Other       10         High school       65         D       10         Some college       12         or above       59         Smoking <sup>+</sup> , n       65         No       16         Yes       16         Yes       16         No       75         Alcohol use <sup>‡</sup> , n       75         No       17         Yes       17         No       13         BMI <sup>§</sup> , kg/m <sup>2</sup> , n (%)       25         < 25	02(78. ) 8(8.82 3(6.14 6(6.99 1(17.8 1(25.6 37(56. ) 81(59. ) 28(40. ) 76(72. ) 3(27.3	1261(77. 96) 435(8.90) 379(6.19) 235(6.96) 235(6.96) 675(16.7 3) 555(25.5 3) 1080(57. 74) 1390(57. 37) 920(42.6 3) 1550(74. 51)	241(78.7 7) 73(8.22) 54(5.81) 31(7.20) 146(25.6 3) 96(26.19 ) 157(48.1 8) 291(72.9 9) 108(27.0 1) 226(59.4	< 0.01 < 0.01	1108(77. 87) 388(9.15) 334(6.24) ) 204(6.75) ) 599(16.8 5) 487(25.2 2) 948(57.9 4) 1227(58. 41) 807(41.5)	394(78.7 1) 120(7.66 ) 99(5.81) 62(7.83) 222(21.1 0) 164(26.9 8) 289(51.9 1) 454(62.1 8) 221(37.8	0.08	1003(80. 02) 298(7.34) 272(5.46) 190(7.18) 460(14.5 0) 433(25.7 5) 870(59.7 5) 1036(55. 58) 727(44.4	499(72.6 3) 210(12.8 8) 161(8.03) 76(6.46) 361(26.8 9) 218(25.2 3) 367(47.8 8) 645(69.3 7) 301(30.6	< 0.01 < 0.01 < 0.01
Hispanic 15 White 06 Non- Hispanic 50 Black 0 Mexican 3 Other 26 ) Education, n (%) Grades 0-12 82 Other 0 Education, n (%) Grades 0-12 82 0) High school graduate/GE 10 Some college 12 or above 59 Smoking*, n (%) Yes 16 Yes 16 No 75 No 75 Alcohol use <sup>‡</sup> , n (%) Yes 17 Yes 17 Some 31 BMI <sup>§</sup> , kg/m <sup>2</sup> , n (%) < 25 31 25-29.9 11 25-29.9 11 Cholesterol, 19 No 93 No 93	) 8(8.82 3(6.14 6(6.99 1(17.8 1(25.6 37(56.) ) 81(59.) 28(40.) ) 76(72.) 3(27.3	96) 435(8.90 ) 379(6.19 ) 235(6.96 ) 675(16.7 3) 555(25.5 3) 1080(57. 74) 1390(57. 37) 920(42.6 3) 1550(74. 51)	7) 73(8.22) 54(5.81) 31(7.20) 146(25.6 3) 96(26.19 ) 157(48.1 8) 291(72.9 9) 108(27.0 1) 226(59.4	0.01 < 0.01	<ul> <li>87)</li> <li>388(9.15)</li> <li>334(6.24)</li> <li>204(6.75)</li> <li>599(16.8</li> <li>5)</li> <li>487(25.2</li> <li>2)</li> <li>948(57.9</li> <li>4)</li> <li>1227(58.</li> <li>41)</li> <li>807(41.5)</li> </ul>	1) 120(7.66 ) 99(5.81) 62(7.83) 222(21.1 0) 164(26.9 8) 289(51.9 1) 454(62.1 8) 221(37.8	0.06	02) 298(7.34 ) 272(5.46 ) 190(7.18 ) 460(14.5 0) 433(25.7 5) 870(59.7 5) 1036(55. 58) 727(44.4	3) 210(12.8 8) 161(8.03 ) 76(6.46) 361(26.8 9) 218(25.2 3) 367(47.8 8) 645(69.3 7) 301(30.6	< 0.0 0.0
Hispanic 50 Black ) Mexican (43) Other 26 <b>Education, n</b> (%) (%) (%) Grades 0–12 (%) Grades 0–12 (%) Grades 0–12 (%) Grades 0–12 (%) Grades 0–12 (%) (%) (%) (%) (%) Some college 12. Or above 59 <b>Smoking<sup>†</sup>, n</b> (%) (%) (%) (%) Yes 16 Xlcohol use <sup>‡</sup> , 17 No 175 Alcohol use <sup>‡</sup> , 17 Yes 17 Yes 17 No 175 Alcohol use <sup>‡</sup> , 17 (%) (%) (%) (%) (%) < 25 (%) (%) (%) (%) (%) (%) (%) (%) (%) (%)	3(6.14 6(6.99 1(17.8 1(25.6 37(56.) ) 81(59.) 28(40.) ) 76(72.) 3(27.3	) 379(6.19 ) 235(6.96 ) 675(16.7 3) 555(25.5 3) 1080(57. 74) 1390(57. 37) 920(42.6 3) 1550(74. 51)	54(5.81) 31(7.20) 146(25.6 3) 96(26.19 ) 157(48.1 8) 291(72.9 9) 108(27.0 1) 226(59.4	0.01 < 0.01	) 334(6.24 ) 204(6.75 ) 599(16.8 5) 487(25.2 2) 948(57.9 4) 1227(58. 41) 807(41.5	) 99(5.81) 62(7.83) 222(21.1 0) 164(26.9 8) 289(51.9 1) 454(62.1 8) 221(37.8	0.06	) 272(5.46 ) 190(7.18 ) 460(14.5 0) 433(25.7 5) 870(59.7 5) 1036(55. 58) 727(44.4	8) 161(8.03 ) 76(6.46) 361(26.8 9) 218(25.2 3) 367(47.8 8) 645(69.3 7) 301(30.6	< (0.0)
Mexican       )         Other       26         Other       )         Education, n       (%)         Grades 0–12       82         O)       0)         High school       65         graduate/GE       1)         Some college       12.         or above       59         Smoking <sup>†</sup> , n       (%)         Yes       16         No       75         Alcohol use <sup>‡</sup> ,       17         Yes       17         No       13         BMI <sup>§</sup> ,       8g/m², n (%)         < 25	6(6.99 1(17.8 1(25.6 37(56.) 81(59.) 28(40.) 76(72.) 3(27.3	) 235(6.96 ) 675(16.7 3) 555(25.5 3) 1080(57. 74) 1390(57. 37) 920(42.6 3) 1550(74. 51)	31(7.20) 146(25.6 3) 96(26.19 ) 157(48.1 8) 291(72.9 9) 108(27.0 1) 226(59.4	0.01 < 0.01	) 204(6.75 ) 599(16.8 5) 487(25.2 2) 948(57.9 4) 1227(58. 41) 807(41.5	62(7.83) 222(21.1 0) 164(26.9 8) 289(51.9 1) 454(62.1 8) 221(37.8	0.06	) 190(7.18 ) 460(14.5 0) 433(25.7 5) 870(59.7 5) 1036(55. 58) 727(44.4	) 76(6.46) 361(26.8 9) 218(25.2 3) 367(47.8 8) 645(69.3 7) 301(30.6	< 0.0 0.0
Other       )         Education, n       (%)         Education, n       (%)         Grades 0–12       0)         High school       65         graduate/GE       1)         Some college       12         or above       59         Smoking <sup>†</sup> , n       (%)         Yes       16         Xlcohol use <sup>‡</sup> , n       (%)         Yes       17         Yes       17         No       10         Smoking <sup>†</sup> , n       (%)         Yes       17         Stational use <sup>‡</sup> , n       (%)         Stational use <sup>‡</sup> , n       17         System       10         No       13         BMI <sup>§</sup> ,       69         kg/m², n (%)       62 $25-29.9$ 11 $\geq 30$ 0)         Total       0)	1(17.8 1(25.6 37(56.) 81(59.) 28(40.) 76(72.) 3(27.3	) 675(16.7 3) 555(25.5 3) 1080(57. 74) 1390(57. 37) 920(42.6 3) 1550(74. 51)	146(25.6 3) 96(26.19) ) 157(48.1 8) 291(72.9 9) 108(27.0 1) 226(59.4	0.01 < 0.01	) 599(16.8 5) 487(25.2 2) 948(57.9 4) 1227(58. 41) 807(41.5	222(21.1 0) 164(26.9 8) 289(51.9 1) 454(62.1 8) 221(37.8	0.06	) 460(14.5 0) 433(25.7 5) 870(59.7 5) 1036(55. 58) 727(44.4	361(26.8 9) 218(25.2 3) 367(47.8 8) 645(69.3 7) 301(30.6	< 0.0 0.0
(%)       82         Grades 0-12       0)         High school       65         graduate/GE       1)         Some college       12.         or above       59.         Smoking*, n       (%)         Yes       16         No       75         Alcohol use*, n       17         Yes       17         No       13         JYes       17         Smoking*, n (%)       93         Yes       17         Some (%)       17         Yes       17         Some (%)       11         Some (%)       11         Yes       17         Some (%)       11         Some (%)       12         Some (%)       11         Some (%)       12         Some (%)       13         Some (%)       14         Some (%)       14         Some (%)	1(25.6 37(56. ) 81(59. ) 28(40. ) 76(72. ) 3(27.3	3) 555(25.5 3) 1080(57. 74) 1390(57. 37) 920(42.6 3) 1550(74. 51)	3) 96(26.19) ) 157(48.1 8) 291(72.9 9) 108(27.0 1) 226(59.4	0.01 < 0.01	5) 487(25.2 2) 948(57.9 4) 1227(58. 41) 807(41.5	0) 164(26.9 8) 289(51.9 1) 454(62.1 8) 221(37.8	0.06	0) 433(25.7 5) 870(59.7 5) 1036(55. 58) 727(44.4	9) 218(25.2 3) 367(47.8 8) 645(69.3 7) 301(30.6	< 0.0 0.0
Grades 0-12       0)         High school       65         graduate/GE       1)         Some college       12.         or above       59         Smoking <sup>†</sup> , n       (%)         Yes       16         Xlcohol use <sup>‡</sup> ,       10.         Yes       17         Yes       17         Yes       17         No       13.         kg/m², n (%)       25         < 25	1(25.6 37(56. ) 81(59. ) 28(40. ) 76(72. ) 3(27.3	3) 555(25.5 3) 1080(57. 74) 1390(57. 37) 920(42.6 3) 1550(74. 51)	3) 96(26.19) ) 157(48.1 8) 291(72.9 9) 108(27.0 1) 226(59.4	0.01	5) 487(25.2 2) 948(57.9 4) 1227(58. 41) 807(41.5	0) 164(26.9 8) 289(51.9 1) 454(62.1 8) 221(37.8	<	0) 433(25.7 5) 870(59.7 5) 1036(55. 58) 727(44.4	9) 218(25.2 3) 367(47.8 8) 645(69.3 7) 301(30.6	0.0
graduate/GE $^{05}$ D       1)         Some college       12.         or above       59.         Smoking <sup>†</sup> , n       (%)         Yes       16.         Yes       16.         No       10.         Yes       16.         Smoking <sup>†</sup> , n       75.         Alcohol use <sup>‡</sup> ,       17.         Yes       17.         Smo       10.         BMI <sup>§</sup> ,       kg/m², n (%)         < 25	37(56. ) 81(59. ) 28(40. ) 76(72. ) 3(27.3	3) 1080(57. 74) 1390(57. 37) 920(42.6 3) 1550(74. 51)	) 157(48.1 8) 291(72.9 9) 108(27.0 1) 226(59.4	0.01	2) 948(57.9 4) 1227(58. 41) 807(41.5	<ul> <li>8)</li> <li>289(51.9</li> <li>1)</li> <li>454(62.1</li> <li>8)</li> <li>221(37.8</li> </ul>	<	5) 870(59.7 5) 1036(55. 58) 727(44.4	3) 367(47.8 8) 645(69.3 7) 301(30.6	0.0
or above 59 <b>Smoking</b> <sup><math>\dagger</math></sup> , n (%) Yes 16 25 No 10 75 <b>Alcohol use<sup>‡</sup></b> , n (%) Yes 17 (%) Yes 17 (%) Yes 17 (%) SMI <sup>8</sup> , 8 <b>kg/m<sup>2</sup></b> , n (%) < 25 62 3) 25-29.9 11. $\geq 30$ 0) Total cholesterol,	) 81(59. ) 28(40. ) 76(72. ) 3(27.3	74) 1390(57. 37) 920(42.6 3) 1550(74. 51)	8) 291(72.9 9) 108(27.0 1) 226(59.4	0.01	4) 1227(58. 41) 807(41.5	1) 454(62.1 8) 221(37.8	<	5) 1036(55. 58) 727(44.4	8) 645(69.3 7) 301(30.6	0.0
(%)       16         Yes       16         No       10         No       75         Alcohol use <sup>‡</sup> ,       17         n (%)       17         Yes       69         No       93         BMI <sup>§</sup> ,       kg/m², n (%)         < 25	) 28(40. ) 76(72. ) 3(27.3	37) 920(42.6 3) 1550(74. 51)	9) 108(27.0 1) 226(59.4	0.01	41) 807(41.5	8) 221(37.8	<	58) 727(44.4	7) 301(30.6	0.0
Yes       25         No       10:         Alcohol use <sup>‡</sup> ,       10:         n (%)       75:         Yes       17:         Yes       69         No       93         BMI <sup>§</sup> ,       8g/m², n (%)         < 25	) 28(40. ) 76(72. ) 3(27.3	37) 920(42.6 3) 1550(74. 51)	9) 108(27.0 1) 226(59.4		41) 807(41.5	8) 221(37.8		58) 727(44.4	7) 301(30.6	
No       75         Alcohol use <sup>‡</sup> ,       75         n (%)       17         Yes       17         Yes       19         No       93         BMI <sup>§</sup> ,       kg/m <sup>2</sup> , n (%)         < 25	) 76(72. ) 3(27.3	3) 1550(74. 51)	1) 226(59.4					· ·		
n (%) Yes 17 69 No 93 BMI <sup>§</sup> , kg/m <sup>2</sup> , n (%) < 25 62 25–29.9 11 7 ≥ 30 94 0) Total cholesterol,	) 3(27.3	51)								
Yes     69       No     93       BMI <sup>§</sup> ,     1)       kg/m², n (%)     62       < 25	) 3(27.3	51)			1376(75	100(62.0	0.01	1212/75	562165 2	< 0.0
NO       1)         BMI*,       kg/m², n (%)         < 25	·	760(25.4	1) 173(40.5		1376(75. 21) 658(24.7	400(63.9 8) 275(36.0		1213(75. 41) 550(24.5	563(65.2 0) 383(34.8	
kg/m², n (%)         < 25		9)	9)		9)	2)		9)	0)	
		505/01 4	100/22.2	0.94	1(2)(2) 2	164/22.4	0.83	207/21 7	220/20.0	0.02
$25-29.9   17 \geq 30   0) Total cholesterol,$		527(21.4 2)	100(22.2 9)		5)	164(22.4 7)		397(21.7 8) 782(45.1	230(20.8 2)	
$\geq 30$ 0) Total cholesterol,	)	982(43.1 4) 801(35.4	157(43.4 2) 142(34.2		863(43.0 3) 708(35.7	276(43.6 5) 235(33.8		783(45.1 9) 583(33.0	356(37.6 1) 360(41.5	
cholesterol,		4)	142(34.2 9)		1)	8)		3)	300(41.3 7)	
				0.02			0.38			< 0.0
< > 11/	· ·	1137(46.	233(55.3		1006(46.	364(49.3		833(44.2	537(55.1	
14	39(52.	02) 1173(53. 98)	1) 166(44.6 9)		51) 1028(53. 49)	1) 311(50.6 9)		2) 930(55.7 8)	8) 409(44.8 2)	
Hypertensio n, n (%)				< 0.01			< 0.01			< 0.0
	<pre></pre>	1188(47. 25)	253(62.9 3)	0.01	1029(46. 53)	412(58.2 0)	0.01	833(44.0 0)	608(63.3 2)	0.0
	68(50.	1122(52. 75)	146(37.0 7)		1005(53. 47)	263(41.8 0)		930(56.0 0)	338(36.6 8)	
Diabetes, n (%)	,		.,	< 0.01	,	-,	0.01	-,	-,	< 0.0
Yes 556		453(13.9 3)	105(24.1 7)		395(13.5 4)	163(20.7 8)		292(11.9 7)	266(23.9 7)	
NO 84		1857(86. 07)	294(75.8 3)		1639(86. 46)	512(79.2 2)		1471(88. 03)	680(76.0 3)	
WBC, 1000 cells/ul, 7.2 mean (SE) 7.2	·	7.22(0.0 7)	7.74(0.1 8)	0.01	7.25(0.0 8)	7.41(0.1 1)	0.22	7.25(0.0 8)	7.38(0.1 2)	0.4
Neu, 1000 cells/ul, 4.3	<b>`</b>	4.31(0.0 6)	4.72(0.0 9)	< 0.01	4.31(0.0 6)	4.51(0.0 8)	0.05	4.33(0.0 7)	4.42(0.0 8)	0.3
Lym, 1000 cells/ul, 2.0	)7(0.0	2.07(0.0 2)	2.13(0.1 2)	0.63	2.09(0.0 3)	2.03(0.0 7)	0.41	2.08(0.0 2)	2.06(0.0 6)	0.8
mean (SE)		0.59(0.0	0.62(0.0	0.06	0.59(0.0	0.59(0.0	0.51	0.58(0.0	0.61(0.0	0.02

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1	
2	
3	
4	
5	
6	
6 7 8	
, o	
0	
9	
10	
11	
12	
13 14	
14	
15	
16	
16 17 18	
18	
19	
20	
21	
22	
22	
24	
25	
26	
26 27 28	
28	
29	
30	
31	
32	
33	
33 34 35	
25	
35 36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
52 53	
22	
54	
55	
56	
57	

58 59 60

cells/ul,	1)	1)	2)		1)	1)		1)	1)	
mean (SE)										
PLT, 1000 cells/ul, mean (SE)	252.30(1 .74)	253.68(1 .92)	242.25(3 .78)	0.01	254.55(1 .70)	244.53(3 .97)	0.02	255.35(2 .23)	243.91(2 .51)	< 0.01
CRP, mg/dl, mean (SE)	0.38(0.0 2)	0.35(0.0 2)	0.63(0.1 4)	0.06	0.35(0.0 2)	0.51(0.0 8)	0.06	0.32(0.0 1)	0.55(0.0 8)	0.01
PIV, mean (SE)	352.79(8 .51)	345.11(8 .45)	408.87(1 8.25)	< 0.01	345.06(9 .09)	379.59(1 4.17)	0.02	342.07(8 .07)	382.35(1 4.59)	< 0.01
SIRI, mean	1.38(0.0	1.34(0.0	1.66(0.0	<	1.33(0.0	1.53(0.0	<	1.32(0.0	1.53(0.0	<
(SE)	3)	3)	6)	0.01	3)	4)	0.01	3)	5)	0.01
SII, mean (SE)	586.41(1 0.55)	577.92(1 1.21)	648.46(2 5.42)	0.01	575.69(1 2.23)	623.61(2 0.14)	0.05	578.16(1 1.65)	609.18(1 6.11)	0.08
NLR, mean	2.32(0.0	2.27(0.0	2.67(0.0	<	2.25(0.0	2.56(0.0	<	2.26(0.0	2.47(0.0	<
(SE)	4)	4)	8)	0.01	4)	7)	0.01	4)	5)	0.01
dNLR,	1.58(0.0	1.55(0.0	1.73(0.0	<	1.54(0.0	1.69(0.0	<	1.56(0.0	1.62(0.0	0.08
mean (SE)	2)	2)	4)	0.01	2)	3)	0.01	2)	3)	0.08
MLR, mean	0.31(0.0	0.31(0.0	0.34(0.0	<	0.30(0.0	0.33(0.0	<	0.30(0.0	0.34(0.0	<
(SE)	0)	0)	1)	0.01	0)	1)	0.01	0)	1)	0.01
PLR, mean	134.99(1	134.75(1	136.73(4	0.67	133.75(1	139.26(4	0.24	134.33(1	136.79(2	0.45
(SE)	.58)	.66)	.45)	0.07	.47)	.43)	0.24	.89)	.68)	0.45
Abbreviations:	LUTS, lowe	r urinary trac	et symptoms	NHANE	S. National H	Health and Nu	utrition E	xamination S	Survey: SE, s	tandard

nptoms NHANES, Natio error; GED, General Equivalency Diploma; BMI, body mass index; WBC, leukocyte; Neu, neutrophil; Lym, lymphocyte; Mono, monocyte; PLT, platelet; CRP, C-reactive protein; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-tolymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio.

\*Means and percentages were adjusted for survey weights of NHANES.

\*Smoking was defined as smoking at least 100 cigarettes during their lifetime.

‡Alcohol use was defined as having at least 12 alcohol drinks in any given year.

\$BMI was calculated by dividing weight in kilograms (kg) by height in meters squared (m<sup>2</sup>). Participants were classified as normal weight (< 25 kg/m<sup>2</sup>), overweight (25–29.9 kg/m<sup>2</sup>), and obese ( $\geq$  30 kg/m<sup>2</sup>).

## 502 503

Table 2. OR (95% CI) for LUTS across quartiles of blood immune-inflammatory indexes\*

	<b>Crude Model</b>	P value	Model 1	P value	Model 2	P value
PIV						
Q1 (< 181.50)	1[Reference]		1[Reference]		1[Reference]	
Q2 (181.50–276.64)	1.15(0.73,1.80)	0.53	1.11(0.69,1.79)	0.65	1.14(0.71,1.85)	0.56
Q3 (276.65–421.83)	0.86(0.59,1.24)	0.39	0.79(0.54,1.17)	0.22	0.82(0.57,1.18)	0.26
Q4 (≥ 421.84)	1.85(1.34,2.56)	< 0.01	1.59(1.14,2.24)	0.01	1.60(1.14,2.23)	0.01
P for trend		< 0.01		0.01		0.02
SIRI						
Q1 (< 0.80)	1[Reference]		1[Reference]		1[Reference]	
Q2 (0.80–1.14)	1.01(0.58,1.73)	0.98	0.98(0.56,1.70)	0.93	0.97(0.55,1.72)	0.92
Q3 (1.15–1.65)	1.39(1.06,1.84)	0.02	1.26(0.94,1.69)	0.12	1.23(0.91,1.66)	0.17
Q4 (≥ 1.66)	2.35(1.61,3.44)	< 0.01	1.91(1.30,2.82)	< 0.01	1.82(1.21,2.73)	0.01
P for trend		< 0.01		< 0.01		< 0.01
SII						
Q1 (< 356.13)	1[Reference]		1[Reference]		1[Reference]	
Q2 (356.13–500.41)	0.97(0.68,1.39)	0.86	0.97(0.65,1.43)	0.86	1.02(0.71,1.48)	0.89
Q3 (500.42–702.31)	0.98(0.67,1.43)	0.91	1.00(0.66,1.51)	0.99	1.04(0.71,1.54)	0.82
Q4 (≥ 702.32)	1.45(1.02,2.06)	0.04	1.37(0.94,2.00)	0.09	1.40(0.97,2.04)	0.07
P for trend		< 0.01		0.03		0.03
NLR						
Q1 (< 1.56)	1[Reference]		1[Reference]		1[Reference]	
Q2 (1.56–2.08)	1.08(0.74,1.60)	0.67	1.15(0.76,1.75)	0.50	1.16(0.75,1.80)	0.48
Q3 (2.09–2.72)	1.75(1.16,2.63)	0.01	1.73(1.12,2.66)	0.02	1.71(1.10,2.66)	0.02
Q4 (≥ 2.73)	2.21(1.60,3.04)	< 0.01	1.89(1.39,2.56)	< 0.01	1.81(1.31,2.49)	< 0.01

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

P for trend		< 0.01		< 0.01		< 0.01
dNLR						
Q1 (< 1.13)	1[Reference]		1[Reference]		1[Reference]	
Q2 (1.13–1.44)	1.09(0.80,1.49)	0.55	1.09(0.80,1.50)	0.56	1.10(0.80,1.51)	0.55
Q3 (1.45–1.84)	1.32(0.92,1.89)	0.12	1.32(0.92,1.89)	0.12	1.33(0.92,1.90)	0.12
Q4 (≥ 1.85)	2.17(1.55,3.04)	< 0.01	1.98(1.42,2.77)	< 0.01	1.91(1.35,2.70)	< 0.01
P for trend		< 0.01		< 0.01		< 0.01
MLR						
Q1 (< 0.22)	1[Reference]		1[Reference]		1[Reference]	
Q2 (0.22–0.29)	1.27(0.72,2.24)	0.39	1.24(0.69,2.25)	0.45	1.25(0.69,2.27)	0.43
Q3 (0.30–0.37)	1.49(0.87,2.56)	0.14	1.38(0.79,2.41)	0.24	1.38(0.77,2.46)	0.26
Q4 (≥ 0.38)	1.96(1.17,3.28)	0.01	1.51(0.89,2.57)	0.12	1.44(0.82,2.53)	0.18
P for trend		< 0.01		0.09		0.16
PLR						
Q1 (< 97.90)	1[Reference]		1[Reference]		1[Reference]	
Q2 (97.90–124.74)	0.94(0.59,1.49)	0.79	0.97(0.61,1.55)	0.90	1.00(0.62,1.62)	0.98
Q3 (124.75–159.41)	0.70(0.49,0.99)	0.04	0.81(0.56,1.18)	0.26	0.86(0.58,1.27)	0.41
Q4 (≥159.42)	1.09(0.72,1.63)	0.68	1.09(0.73,1.64)	0.65	1.14(0.74,1.74)	0.53
P for trend		0.77		0.70		0.57
CRP, mg/dl						
Q1 (< 0.09)	1[Reference]		1[Reference]		1[Reference]	
Q2 (0.09–0.20)	0.88(0.56,1.38)	0.57	0.84(0.53,1.34)	0.45	0.83(0.51,1.34)	0.41
Q3 (0.21–0.43)	1.12(0.66,1.92)	0.66	1.05(0.59,1.88)	0.86	1.05(0.58,1.88)	0.87
Q4 (≥ 0.43)	2.03(1.28,3.22)	< 0.01	1.78(1.09,2.90)	0.02	1.71(1.05,2.79)	0.03
P for trend		< 0.01		< 0.01		< 0.01

Abbreviations: *OR*, odds ratio; *CI*, confidence interval; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein. \*Values are numerical values or weighted *OR* (95% *CI*).

Model 1 was adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI;


Model 2 was additionally adjusted for total cholesterol, and a history of diabetes and hypertension

## 

Table 3. OR (95% CI) for clinical LUTS across combined blood immune-inflammatory indexes\*

	Crude Model	P value	Model 1	P value	Model 2	P value		
SIRI+CRP (Low SIRI < 1.14, High SIRI $\geq$ 1.14; Low CRP < 0.43, High CRP $\geq$ 0.43)								
Low SIRI and Low CRP	1[Reference]		1[Reference]		1[Reference]			
High SIRI and Low CRP	1.83(1.34,2.50)	< 0.01	1.60(1.13,2.25)	0.01	1.56(1.10,2.21)	0.02		
Low SIRI and High CRP	2.28(1.28,4.07)	0.01	2.15(1.12,4.14)	0.02	2.10(1.09,4.03)	0.03		
High SIRI and High CRP	2.90(2.04,4.12)	< 0.01	2.39(1.65,3.48)	< 0.01	2.26(1.56,3.26)	< 0.01		
NLR+CRP (Low NLR < 2.	08, High NLR ≥ 2.0	08)						
Low NLR and Low CRP	1[Reference]		1[Reference]		1[Reference]			
High NLR and Low CRP	2.06(1.54,2.77)	< 0.01	1.82(1.37,2.41)	< 0.01	1.78(1.33,2.38)	< 0.01		
Low NLR and High CRP	2.69(1.57,4.62)	< 0.01	2.40(1.33,4.32)	0.01	2.31(1.29,4.14)	0.01		
High NLR and High CRP	3.07(2.11,4.46)	< 0.01	2.59(1.73,3.86)	< 0.01	2.44(1.60,3.71)	< 0.01		
dNLR+CRP (Low dNLR <	1.84, High dNLR	≥ 1.84)						
Low dNLR and Low CRP	1[Reference]		1[Reference]		1[Reference]			
High dNLR and Low CRP	2.03(1.39,2.97)	< 0.01	1.88(1.24,2.84)	< 0.01	1.87(1.22,2.87)	0.01		
Low dNLR and High CRP	2.16(1.37,3.41)	< 0.01	2.01(1.23,3.26)	0.01	1.99(1.23,3.23)	0.01		

	High dNLR and High CRP $2.84(1.66,4.87)$ $< 0.01$ $2.38(1.35,4.21)$ $< 0.01$ $2.16(1.21,3.87)$ $0.01$ Abbreviations: OR, odds ratio; CI, confidence interval; SIRI, system inflammation response index; NLR, neutrophil to
	Abbreviations: <i>OR</i> , odds ratio; <i>CI</i> , confidence interval; SIRI, system inflammation response index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; CRP, C-reactive protein. *Values are numerical values or weighted <i>OR</i> (95% <i>CI</i> ). Model 1 was adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI; Model 2 was additionally adjusted for total cholesterol, and a history of diabetes and hypertension.
505	



539x488mm (300 x 300 DPI)

Markers	Age < 60 years OR (95%Cl)	Age > 60 years OR (95%Cl)	Smoking (No) OR (95%Cl)	Smoking (Yes) OR (95%Cl)	Hypertension (No) OR (95%Cl)	Hypertension (Yes OR (95%CI)
PIV						
Q2 VS Q1	· · · · · · · · · · · · · · · · · · ·	<b></b>	<b>→</b>	<b>—</b>	· · · · · · · · · · · · · · · · · · ·	
Q3 VS Q1	Here a				H	
Q4 VS Q1						
SIRI	:		:	:	:	:
Q2 VS Q1	H	<b>—</b>				<b>—</b>
Q3 VS Q1		· · · · · · · · · · · · · · · · · · ·				
Q4 VS Q1		·→	H		· · · · · · · · · · · · · · · · · · ·	
SII	:	:	:	:	:	:
Q2 VS Q1	H H			<b>H</b>	H-H-H-H-H-H-H-H-H-H-H-H-H-H-H-H-H-H-H-	<b>H</b>
Q3 VS Q1	H	<b>H</b>				<b>H</b>
Q4 VS Q1					· · · · · · · · · · · · · · · · · · ·	
NLR	:	:	:	:	:	:
Q2 VS Q1		<b>—</b>		<b>—</b>	<b></b>	
Q3 VS Q1		<b>→</b>				
Q4 VS Q1		→ → →	· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·
dNLR	:	:	:	:	:	:
Q2 VS Q1		H-H-H		<b>H</b>	H-H-H-H	
Q3 VS Q1						
Q4 VS Q1	i i i i i i i i i i i i i i i i i i i	$\longrightarrow$			· · · · · · · · · · · · · · · · · · ·	
MLR	:	:	:	:	:	:
Q2 VS Q1	<b>—</b>			H-H-H-H-H-H-H-H-H-H-H-H-H-H-H-H-H-H-H-		<b>—</b>
Q3 VS Q1						
Q4 VS Q1				· · · · · · · · · · · · · · · · · · ·		
PLR	:	:	:	:	:	:
Q2 VS Q1		<b></b>				<b>—</b>
Q3 VS Q1	H	<b>—</b>	H			
Q4 VS Q1	<b></b>				· · · · · · · · · · · · · · · · · · ·	
CRP	:	:	:	:	:	:
Q2 VS Q1					<b>—</b>	
Q3 VS Q1	H		H		H	H-1
Q4 VS Q1						
	20.5 1 2 3 3.	5 0.5 1 2 3 3.5	50.2 0.5 1 2 3 3		.50.2 0.5 1 2 3 3.5	5 0.5 1 2

Fig. 2 Associations between blood immune-inflammatory indexes and clinical LUTS in subgroup analyses. They are adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI, total cholesterol, and a history of diabetes and hypertension, if not already stratified. Abbreviations: OR, odds ratio; LUTS, lower urinary tract symptoms; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein.

311x220mm (300 x 300 DPI)

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

-						
	Crude Model	P value	Model 1	P value	Model 2	P value
PIV	1.15(1.06,1.24)	< 0.01	1.10(1.02,1.19)	0.02	1.08(1.00,1.18)	0.06
SIRI	1.27(1.17,1.37)	< 0.01	1.18(1.09,1.28)	< 0.01	1.16(1.06,1.26)	< 0.01
SII	1.13(1.03,1.24)	0.01	1.12(1.02,1.22)	0.02	1.10(1.01,1.21)	0.03
NLR	1.28(1.15,1.42)	< 0.01	1.22(1.11,1.34)	< 0.01	1.20(1.10,1.32)	< 0.01
dNLR	1.18(1.06,1.31)	< 0.01	1.16(1.06,1.28)	< 0.01	1.15(1.05,1.25)	< 0.01
MLR	1.27(1.17,1.37)	< 0.01	1.17(1.06,1.28)	< 0.01	1.16(1.05,1.27)	< 0.01
PLR	1.09(1.06,1.24)	< 0.01	1.09(0.98,1.20)	0.10	1.10(1.00,1.22)	0.06
CRP, mg/dl	1.20(1.13,1.27)	< 0.01	1.20(1.13,1.26)	< 0.01	1.19(1.12,1.27)	< 0.01

**Supplementary table 1.** Multivariate logistic ordinal regression analysis of the blood immune-inflammatory indexes among the number of positive symptoms associated with clinical LUTS<sup>\*</sup>

Abbreviations: *OR*, odds ratio; *CI*, confidence interval; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein. \*Values are numerical values or weighted *OR* (95% *CI*).

Model 1 was adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI;

Model 2 was additionally adjusted for total cholesterol, and a history of diabetes and hypertension.

## BMJ Open

Model 1

1[Reference]

P value

Model 2

1[Reference]

P value

Supplementary table 2.	
	Crude Model
PIV	
Q1 (< 181.50)	1[Reference]
Q2 (181.50–276.64)	1.20(0.83,1.71)
Q3 (276.65–421.83)	0.95(0.65,1.40)
Q4 (≥421.84)	1.46(0.96,2.21)
<i>P</i> for trend	
SIRI	
Q1 (< 0.80)	1[Reference]
Q2 (0.80–1.14)	1.08(0.62,1.88)
Q3 (1.15–1.65)	1.14(0.76,1.71)
Q4 (≥ 1.66)	1.82(1.05,3.17)
P for trend	
SII	
Q1 (< 356.13)	1[Reference]
Q2 (356.13-500.41)	1.00(0.72,1.39)
Q3 (500.42-702.31)	1.03(0.71,1.49)
Q4 (≥ 702.32)	1.32(0.89,1.95)
<i>P</i> for trend	
NLR	
Q1 (< 1.56)	1[Reference]
Q2 (1.56–2.08)	1.18(0.92,1.52)
Q3 (2.09–2.72)	1.41(0.91,2.18)
Q3(2.03)(2.172) $Q4(\geq 2.73)$	2.10(1.44,3.05)
$Q^{4} (\geq 2.73)$ P for trend	2.10(1.44,5.05)
dNLR	
Q1 (< 1.13)	1[Reference]
Q2 (1.13–1.44)	1.25(0.98,1.61)
Q3 (1.45–1.84)	1.20(0.78,1.83)
Q4 (≥ 1.85)	1.99(1.35,2.93)
<i>P</i> for trend	
MLR	
Q1 (< 0.22)	1[Reference]
Q2 (0.22–0.29)	1.17(0.81,1.69)
Q3 (0.30–0.37)	1.32(0.85,2.06)
Q4 (≥ 0.38)	1.66(1.14,2.42)
P for trend	
PLR	
Q1 (< 97.90)	1[Reference]
Q2 (97.90–124.74)	0.92(0.65,1.30)
Q3 (124.75–159.41)	0.76(0.60,0.96)
Q4 (≥ 159.42)	1.13(0.82,1.57)
$Q \cdot (\underline{P} \text{ result})$ <i>P</i> for trend	- (
CRP, mg/dl	
Q1 (< 0.09)	1[Reference]
×1 ( · 0.07)	Treferencej

I[Itelefenee]		I[Itereference]		I[Itelefelee]	
1.20(0.83,1.71)	0.32	1.16(0.79,1.69)	0.44	1.17(0.80,1.71)	0.39
0.95(0.65,1.40)	0.81	0.91(0.62,1.34)	0.62	0.93(0.63,1.35)	0.67
1.46(0.96,2.21)	0.07	1.33(0.87,2.03)	0.17	1.32(0.85,2.03)	0.20
	0.07		0.16		0.22
1[Reference]		1[Reference]		1[Reference]	
1.08(0.62,1.88)	0.77	1.05(0.60,1.86)	0.85	1.04(0.58,1.86)	0.88
1.14(0.76,1.71)	0.51	1.05(0.68,1.62)	0.81	1.01(0.66,1.57)	0.94
1.82(1.05,3.17)	0.03	1.59(0.89,2.85)	0.11	1.52(0.83,2.80)	0.16
	< 0.01		0.04		0.07
1[Reference]		1[Reference]		1[Reference]	
1.00(0.72,1.39)	0.99	0.99(0.69,1.42)	0.96	1.03(0.73,1.45)	0.86
1.03(0.71,1.49)	0.86	1.02(0.70,1.51)	0.90	1.05(0.71,1.54)	0.81
1.32(0.89,1.95)	0.16	1.27(0.84,1.93)	0.25	1.28(0.83,1.96)	0.24
	0.11		0.17		0.19
1[Reference]		1[Reference]		1[Reference]	
1.18(0.92,1.52)	0.19	1.19(0.90,1.57)	0.20	1.18(0.89,1.58)	0.23
1.41(0.91,2.18)	0.12	1.34(0.85,2.10)	0.19	1.32(0.83,2.09)	0.22
2.10(1.44,3.05)	< 0.01	1.87(1.26,2.78)	< 0.01	1.82(1.21,2.73)	0.01
	< 0.01		< 0.01		< 0.01
1[Reference]		1[Reference]		1[Reference]	
1.25(0.98,1.61)	0.07	1.23(0.95,1.59)	0.11	1.23(0.95,1.59)	0.11
1.20(0.78,1.83)	0.39	1.15(0.74,1.78)	0.51	1.15(0.74,1.79)	0.51
1.99(1.35,2.93)	< 0.01	1.86(1.25,2.75)	< 0.01	1.81(1.20,2.71)	0.01
	< 0.01		< 0.01		0.01
1[Reference]		1[Reference]		1[Reference]	
1.17(0.81,1.69)	0.38	1.13(0.77,1.66)	0.50	1.13(0.77,1.66)	0.49
1.32(0.85,2.06)	0.20	1.23(0.77,1.96)	0.36	1.22(0.75,1.98)	0.40
1.66(1.14,2.42)	0.01	1.38(0.93,2.04)	0.10	1.35(0.89,2.03)	0.15
	0.01		0.13		0.19
1[Reference]		1[Reference]		1[Reference]	
0.92(0.65,1.30)	0.63	0.93(0.66,1.32)	0.68	0.94(0.66,1.34)	0.71
0.76(0.60,0.96)	0.02	0.81(0.64,1.04)	0.09	0.83(0.65,1.07	0.14
1.13(0.82,1.57)	0.44	1.11(0.80,1.55)	0.50	1.13(0.80,1.60)	0.45
	0.47		0.52		0.45
1[D of or on co]		1[D of or on a a]		1[Deference]	
1[Reference]		1[Reference]		1[Reference]	

upplementary table 2. OR (95% CI) for daytime LUTS across quartiles of blood immune-inflammatory indexes\*

P value

		1 8 77 7				
P for trend		0.02		0.03		0.05
Q4 (≥ 0.43)	1.36(0.97,1.91)	0.07	1.29(0.90,1.85)	0.15	1.22(0.86,1.74)	0.25
Q3 (0.21–0.43)	0.95(0.66,1.37)	0.79	0.95(0.64,1.39)	0.76	0.92(0.63,1.36)	0.66
Q2 (0.09–0.20)	0.84(0.62,1.15)	0.28	0.83(0.59,1.16)	0.26	0.82(0.58,1.16)	0.23

Abbreviations: *OR*, odds ratio; *CI*, confidence interval; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein. \*Values are numerical values or weighted *OR* (95% *CI*).

Model 1 was adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI;

Model 2 was additionally adjusted for total cholesterol, and a history of diabetes and hypertension.

to beet terien only

$\begin{array}{c}1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\2\\13\\14\\15\\16\\17\\8\\9\\20\\21\\22\\34\\25\\26\\7\\28\\9\\30\\31\\23\\34\\5\\6\\7\\8\\9\\40\\41\\2\\3\\44\\5\\46\\7\\8\\9\\40\\41\\2\\3\\44\\5\\46\\7\\8\\9\\40\\41\\2\\3\\4\\45\\46\\7\\8\\9\\40\\41\\2\\3\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\8\\9\\40\\41\\2\\3\\4\\5\\6\\7\\8\\8\\9\\6\\6\\8\\8\\8\\6\\8\\8\\8\\8\\8\\6\\8\\8\\8\\8\\8$	
43 44 45 46 47	

Supplementary table 3.	· ·	-				
	Crude Model	P value	Model 1	P value	Model 2	Р
PIV						
Q1 (< 181.50)	1[Reference]		1[Reference]		1[Reference]	
Q2 (181.50–276.64)	0.95(0.66,1.36)	0.77	0.96(0.65,1.43)	0.84	0.98(0.65,1.50)	
Q3 (276.65–421.83)	0.91(0.63,1.33)	0.63	0.88(0.58,1.34)	0.55	0.91(0.59,1.41)	
Q4 (≥ 421.84)	1.34(1.02,1.77)	0.04	1.26(0.94,1.70)	0.12	1.25(0.91,1.71)	
<i>P</i> for trend		0.01		0.06		
SIRI						
Q1 (< 0.80)	1[Reference]		1[Reference]		1[Reference]	
Q2 (0.80–1.14)	0.84(0.61,1.15)	0.27	0.87(0.61,1.22)	0.39	0.86(0.60,1.22)	
Q3 (1.15–1.65)	1.26(0.89,1.77)	0.18	1.20(0.80,1.80)	0.36	1.17(0.76,1.81)	
Q4 (≥ 1.66)	1.58(1.16,2.16)	0.01	1.39(1.00,1.94)	0.05	1.30(0.92,1.84)	
P for trend		< 0.01		0.01		
SII						
Q1 (< 356.13)	1[Reference]		1[Reference]		1[Reference]	
Q2 (356.13–500.41)	0.78(0.57,1.07)	0.12	0.78(0.57,1.08)	0.12	0.82(0.60,1.12)	
Q3 (500.42-702.31)	0.79(0.60,1.04)	0.10	0.85(0.63,1.14)	0.26	0.87(0.65,1.17)	
Q4 (≥ 702.32)	1.03(0.78,1.38)	0.81	1.03(0.78,1.37)	0.81	1.04(0.78,1.40)	
P for trend		0.39		0.36		
NLR						
Q1 (< 1.56)	1[Reference]		1[Reference]		1[Reference]	
Q2 (1.56–2.08)	0.83(0.54,1.27)	0.37	0.95(0.61,1.47)	0.81	0.94(0.59,1.48)	
Q3 (2.09–2.72)	1.20(0.86,1.66)	0.27	1.25(0.88,1.79)	0.20	1.23(0.86,1.76)	
Q4 (≥ 2.73)	1.45(1.04,2.02)	0.03	1.32(0.94,1.87)	0.10	1.25(0.88,1.77)	
P for trend		< 0.01		0.03		
dNLR						
Q1 (< 1.13)	1[Reference]		1[Reference]		1[Reference]	
Q2 (1.13–1.44)	0.97(0.69,1.37)	0.85	1.03(0.70,1.51)	0.88	1.02(0.68,1.53)	
Q3 (1.45–1.84)	1.04(0.75,1.44)	0.83	1.11(0.78,1.60)	0.53	1.11(0.78,1.59)	
Q4 (≥ 1.85)	1.24(0.88,1.76)	0.22	1.18(0.82,1.70)	0.36	1.13(0.77,1.65)	
P for trend		0.16		0.29		
MLR						
Q1 (< 0.22)	1[Reference]		1[Reference]		1[Reference]	
Q2 (0.22–0.29)	0.88(0.62,1.24)	0.45	0.92(0.65,1.30)	0.62	0.92(0.65,1.30)	
Q3 (0.30–0.37)	1.34(0.97,1.87)	0.08	1.37(1.00,1.87)	0.05	1.37(0.98,1.89)	
Q4 (≥ 0.38)	1.83(1.32,2.53)	< 0.01	1.56(1.13,2.16)	0.01	1.49(1.07,2.08)	
P for trend	,	< 0.01	,	< 0.01		<

P for trend		< 0.01		< 0.01		< 0.01
PLR						
Q1 (< 97.90)	1[Reference]		1[Reference]		1[Reference]	
Q2 (97.90–124.74)	0.79(0.56,1.11)	0.17	0.80(0.56,1.15)	0.21	0.84(0.57,1.24)	0.36
Q3 (124.75–159.41)	0.80(0.62,1.04)	0.09	0.94(0.74,1.20)	0.62	1.02(0.79,1.32)	0.86
Q4 (≥159.42)	1.01(0.70,1.45)	0.96	1.02(0.72,1.45)	0.91	1.08(0.74,1.56)	0.67
P for trend		0.74		0.54		0.40
CRP, mg/dl						
Q1 (< 0.09)	1[Reference]		1[Reference]		1[Reference]	

Q2 (0.09–0.20)	1.13(0.80,1.61)	0.47	1.07(0.76,1.51)	0.70	1.04(0.75,1.46)	0.23
Q3 (0.21–0.43)	1.39(0.98,1.98)	0.06	1.18(0.81,1.71	0.38	1.16(0.80,1.69)	0.66
Q4 (≥ 0.43)	2.19(1.61,2.98)	< 0.01	1.67(1.14,2.43)	0.01	1.59(1.08,2.34)	0.02
P for trend		< 0.01		< 0.01		< 0.01


Abbreviations: *OR*, odds ratio; *CI*, confidence interval; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein. \*Values are numerical values or weighted *OR* (95% *CI*).

Model 1 was adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI;

Model 2 was additionally adjusted for total cholesterol, and a history of diabetes and hypertension.

for per terien on


Page 31 of 34




166x156mm (300 x 300 DPI)

BMJ Open: first published as 10.1136/bmjopen-2023-080826 on 23 March 2024. Downloaded from http://bmjopen.bmj.com/ on June 10, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**BMJ** Open





		BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open	Page				
STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of creases dectional studies							
Section/Topic	Item #	Recommendation	Reported on page #				
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what vase found (b) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informati	1				
		៉ូវ ស៊ី ទី (b) Provide in the abstract an informative and balanced summary of what was done and what væggfound	1-2				
Introduction	•	aner atee					
Background/rationale	2		2-3				
Objectives	3	State specific objectives, including any prespecified hypotheses	3				
Methods		and					
Study design	4	Present key elements of study design early in the paper	3				
Setting	5	Present key elements of study design early in the paper Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, by y-up, and data collection	3-4				
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	3-4				
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers Give diagnostic criteria, if	3-4				
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe	3-4				
Bias	9	Describe any efforts to address potential sources of bias	3-4				
Study size	10	Explain how the study size was arrived at	3				
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	3-4				
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	4-5				
		(b) Describe any methods used to examine subgroups and interactions	4-5				
		(c) Explain how missing data were addressed	4-5				
		(d) If applicable, describe analytical methods taking account of sampling strategy	4-5				
		(e) Describe any sensitivity analyses	4-5				
Results		ů high state stat					

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

34		BMJ Open BMJ Open-2023						
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, exangine for eligibility,	5					
		confirmed eligible, included in the study, completing follow-up, and analysed	5					
		(c) Consider use of a flow diagram	5					
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on a subscription of the second potential confounders	5					
		(b) Indicate number of participants with missing data for each variable of interest	5					
Outcome data	15*	Report numbers of outcome events or summary measures	5-7					
Main results	16	confounders       i i i i i i i i i i i i i i i i i i i	5-7					
		interval). Make clear which confounders were adjusted for and why they were included <sup>x</sup> y y <sup>x</sup> y	5-7					
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful and be a seried	5-7					
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	7					
Discussion		nng.						
Key results	18	Summarise key results with reference to study objectives	8					
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Dia us both direction and magnitude of any potential bias	8-10					
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	8-10					
Generalisability	21	Discuss the generalisability (external validity) of the study results	8-10					
Other information		ar t						
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, by original study on which the present article is based	11					

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in controls in case-control studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published exan bles of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine  $\mathbb{F}rg/$ , Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.spidem.com/).

raphique

del

# Association between immune-inflammatory indexes and lower urinary tract symptoms: an analysis of cross-sectional data from the US National Health and Nutrition Examination Survey (2005–2008)

	1
Journal:	BMJ Open
Manuscript ID	bmjopen-2023-080826.R1
Article Type:	Original research
Date Submitted by the Author:	21-Feb-2024
Complete List of Authors:	liu, wen; Chinese Academy of Medical Sciences & Peking Union Medical College, Wang, Jia; The Affiliated Hospital of Qingdao University, Department of Gastroenterology Wang, Miaomiao; Chinese Academy of Medical Sciences, Department of Urology; Chinese Academy of Medical Sciences Ding, Xin; Beijing Hospital, Department of Urology Wang, Miao; Chinese Academy of Medical Sciences, Department of Urology Liu, Ming; Chinese Academy of Medical Sciences, Department of Urology; Chinese Academy of Medical Sciences, Department of Urology;
<b>Primary Subject Heading</b> :	Urology
Secondary Subject Heading:	Urology
Keywords:	Prostate, Prostate disease < UROLOGY, Kidney & urinary tract disorders < UROLOGY

# SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1	Association between immune-inflammatory indexes and lower urinary tract
2	symptoms: an analysis of cross-sectional data from the US National Health and
3	Nutrition Examination Survey (2005–2008)
4	
5	Wen Liu <sup>1,2†</sup> , Jia Wang <sup>3†</sup> , Miaomiao Wang <sup>1,2</sup> , Xin Ding <sup>1</sup> , Miao Wang <sup>1*</sup> , and Ming Liu <sup>1,2*</sup>
6	
7	1 Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric
8	Medicine, Chinese Academy of Medical Sciences, Beijing, China.
9	2 Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing,
10	China.
11	3 Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong,
12	China.
13	
14	† Both authors contributed equally to this work
15	
16	*Correspondence to:
17	Ming Liu
18	Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric
19	Medicine, Chinese Academy of Medical Sciences, No.1 DaHua Road, Dong Dan, Beijing, 100730,
20	China. E-mail: liumingbjh@126.com
21	E-mail: liumingbjh@126.com
22	
23	Abstract
24	Objective This study aimed to systematically investigate the relationship between immune-
25	inflammatory indexes with lower urinary tract symptoms (LUTS).
26	Design Cross-sectional study.
27	Setting National Health and Nutrition Examination Survey (NHANES) (2005–2008).
28	Participants A total of 2,709 men with complete information for immune-inflammatory indexes and
29	LUTS were included from NHANES 2005–2008.
30	Outcomes and analyses Automated haematology analysing devices are used to measure blood cell
	1

Page 3 of 34

# **BMJ** Open

31	counts, and LUTS were presented by standard questionnaires. Nonlinear and logistic regression
32	analysis were used to estimate their association after adjustment for confounders.
33	<b>Results</b> Multivariate logistic regression showed that PIV (OR [95% CI] = 1.60 [1.14–2.23]), SIRI (OR
34	[95% CI] = 1.82 [1.21–2.73]), NLR (OR [95% CI] = 1.81 [1.31–2.49]), dNLR (OR [95% CI] = 1.91
35	[1.35–2.70]), and CRP (OR [95% CI] = 1.71 [1.05–2.79]) was positively associated with LUTS.
36	Additionally, composite immune-inflammation markers exhibited a stronger association with LUTS
37	than any single index, with the ORs for high SIRI+high CRP, high NLR+high CRP, and high
38	dNLR+high CRP being 2.26, 2.44, and 2.16, respectively (All $P < 0.05$ ). Furthermore, subgroup
39	analyses revealed that age, smoking status, and hypertension have different effects on the relationship
40	between immune-inflammatory markers and LUTS.
41	Conclusions This study indicated that high levels of immune-inflammatory markers were associated
42	with an increased risk of clinical LUTS. The combination of CRP with SIRI, NLR, and dNLR
43	respectively showed a stronger positive correlation with clinical LUTS compared to any single index.
44	
45	Keywords: NHANES; Lower urinary tract symptoms; prostatic hyperplasia; immune-inflammatory
46	index; inflammation
46 47	index; inflammation
	index; inflammation STRENGTHS AND LIMITATIONS OF THIS STUDY
47	
47 48	STRENGTHS AND LIMITATIONS OF THIS STUDY
47 48 49	• The NHANES dataset, representing the national population, enhances the generalisability
47 48 49 50	<ul> <li>STRENGTHS AND LIMITATIONS OF THIS STUDY</li> <li>The NHANES dataset, representing the national population, enhances the generalisability of our findings to a broader context.</li> </ul>
47 48 49 50 51	<ul> <li>STRENGTHS AND LIMITATIONS OF THIS STUDY</li> <li>The NHANES dataset, representing the national population, enhances the generalisability of our findings to a broader context.</li> <li>This study investigated the correlation between various immune-inflammatory indexes, as</li> </ul>
47 48 49 50 51 52	<ul> <li>STRENGTHS AND LIMITATIONS OF THIS STUDY</li> <li>The NHANES dataset, representing the national population, enhances the generalisability of our findings to a broader context.</li> <li>This study investigated the correlation between various immune-inflammatory indexes, as well as composite markers, and lower urinary tract symptoms (LUTS).</li> </ul>
47 48 49 50 51 52 53	<ul> <li>STRENGTHS AND LIMITATIONS OF THIS STUDY</li> <li>The NHANES dataset, representing the national population, enhances the generalisability of our findings to a broader context.</li> <li>This study investigated the correlation between various immune-inflammatory indexes, as well as composite markers, and lower urinary tract symptoms (LUTS).</li> <li>It is important to recognise that drawing causal conclusions from cross-sectional analyses</li> </ul>
47 48 49 50 51 52 53 54	<ul> <li>STRENGTHS AND LIMITATIONS OF THIS STUDY</li> <li>The NHANES dataset, representing the national population, enhances the generalisability of our findings to a broader context.</li> <li>This study investigated the correlation between various immune-inflammatory indexes, as well as composite markers, and lower urinary tract symptoms (LUTS).</li> <li>It is important to recognise that drawing causal conclusions from cross-sectional analyses</li> </ul>
47 48 49 50 51 52 53 54 55	<ul> <li>STRENGTHS AND LIMITATIONS OF THIS STUDY</li> <li>The NHANES dataset, representing the national population, enhances the generalisability of our findings to a broader context.</li> <li>This study investigated the correlation between various immune-inflammatory indexes, as well as composite markers, and lower urinary tract symptoms (LUTS).</li> <li>It is important to recognise that drawing causal conclusions from cross-sectional analyses presents challenges.</li> </ul>
47 48 49 50 51 52 53 54 55 56	<ul> <li>STRENGTHS AND LIMITATIONS OF THIS STUDY</li> <li>The NHANES dataset, representing the national population, enhances the generalisability of our findings to a broader context.</li> <li>This study investigated the correlation between various immune-inflammatory indexes, as well as composite markers, and lower urinary tract symptoms (LUTS).</li> <li>It is important to recognise that drawing causal conclusions from cross-sectional analyses presents challenges.</li> </ul>
47 48 49 50 51 52 53 54 55 56 57	<ul> <li>STRENGTHS AND LIMITATIONS OF THIS STUDY</li> <li>The NHANES dataset, representing the national population, enhances the generalisability of our findings to a broader context.</li> <li>This study investigated the correlation between various immune-inflammatory indexes, as well as composite markers, and lower urinary tract symptoms (LUTS).</li> <li>It is important to recognise that drawing causal conclusions from cross-sectional analyses presents challenges.</li> </ul>
47 48 49 50 51 52 53 54 55 56 57 58	<ul> <li>STRENGTHS AND LIMITATIONS OF THIS STUDY</li> <li>The NHANES dataset, representing the national population, enhances the generalisability of our findings to a broader context.</li> <li>This study investigated the correlation between various immune-inflammatory indexes, as well as composite markers, and lower urinary tract symptoms (LUTS).</li> <li>It is important to recognise that drawing causal conclusions from cross-sectional analyses presents challenges.</li> <li>INTRODUCTION</li> <li>Lower urinary tract symptoms (LUTS) are a common complaint among aging men, with approximately 80% experiencing at least one urine symptom by the age of 80(1). LUTS is now widely recognised as a</li> </ul>

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

million is spent annually on LUTS drugs, which can impose a heavy strain on the economy and public
health(4, 5). Thus, it is essential to identify the factors that contribute to the development and
progression of LUTS in aging men.

Several inflammatory markers, including the pan-immune-inflammation value (PIV), systemic (SIRI), inflammation response index systemic immune-inflammation index (SII), neutrophil/lymphocyte (NLR), derived neutrophil/lymphocyte (dNLR), ratio ratio monocyte/lymphocyte ratio (MLR), platelet/lymphocyte ratio (PLR), and C-reactive protein (CRP), have been considered in the development and progression of inflammatory and infectious diseases(6-10). Interestingly, studies have also identified positive associations between inflammatory markers, such as CRP(10-12) and NLR(13, 14), and the risk of LUTS, suggesting that inflammation may play an important role in the development of LUTS. For instance, prostate tissue samples taken from individuals with benign prostatic hyperplasia (BPH), a condition often associated with LUTS resulting from bladder outlet obstruction, commonly exhibit acute and chronic inflammation(2, 15, 16). Additionally, inflammation may contribute to overactive bladder, which is another cause of LUTS(2, 17).

In recent years, a number of new inflammatory markers, such as PIV(18), SIRI(19), and SII(19), have been developed, yet no study has explored their relationship with LUTS. Furthermore, using these markers as single risk factors for LUTS could be limited by their low discriminatory power. Since the interplay between immunity, inflammation, and diseases involve complex networks, composite markers would be a more accurate and meaningful approach to capture the overall inflammatory status and reflect various immuno-inflammatory populations(20-22). Therefore, this study aims to systematically investigate the relationship between blood immune-inflammatory indexes and their combinations with LUTS, using representative NHANES data. This study sought to advance the understanding of the pathogenesis of LUTS and provide insights for potential interventions.

85 METHODS

# 86 Study design and participants

87 The NHANES is a cross-sectional survey that employs a sophisticated multistage sample methodology 88 to investigate the health and nutritional status of the non-institutionalised population in the US. The 89 demographic information used in this study was obtained from the NHANES, and the protocol was 90 approved by the National Center for Health Statistics Ethics Review Board. Written informed consent

## **BMJ** Open

was obtained from all participants, and all NHANES data is publicly available on the relevant website(23).

In this study, we used publicly accessible data from two 2-year cycles of NHANES (2005-2006, 2007-2008) and restricted the analysis cohort to men aged 40 years or older. Initially, there were 3,506 male participants aged 40 years and older in our data. We excluded 417 participants with incomplete LUTS status and 150 participants with a history of prostate cancer. Additionally, 230 participants with incomplete variables data were excluded. Finally, 2,709 participants were included in this study (Supplementary Figure 1).

Questionnaire data assessment

LUTS were assessed by four questions, including: (1) "Do you usually have trouble starting to urinate (pass water)?" (hesitancy, defined as the answer is yes); (2) "After urinating (passing water), does your bladder feel empty?" (incomplete emptying, defined as the answer is no); (3) "How often do you have urinary leakage?" (urinary frequency, defined as the answer is 1 or greater); (4) "During the past 30 days, how many times per night did you most typically get up to urinate, from the time you went to bed at night until the time you got up in the morning?" (nocturia, defined as an answer is 2 or greater). Daytime LUTS was defined as a participant with one or more of the first three symptoms listed above. Clinical LUTS was defined as a participant having two or more of the mentioned symptoms(1).

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### **Definition of immune-inflammation indexes**

Automated haematology analysing devices (Coulter DxH 800 analyzer) are used to measure lymphocyte, neutrophil, monocyte, and platelet count, which are presented as  $\times 10^{\$}3$  cells/µl. The Behring Nephelometer is used to measure serum CRP levels by latex-enhanced nephelometry, with a lower limit of detection (LLOD) of 0.2 mg/L. The immune-inflammatory indexes in our study were calculated as follows:  $PIV = platelet \times neutrophil \times monocyte /lymphocyte(18); SIRI = neutrophil$  $\times$  monocyte/lymphocyte(19); SII = platelet  $\times$  neutrophil/lymphocyte(24); NLR neutrophil/lymphocyte(24); dNLR neutrophil/(leukocyte-neutrophil)(25); MLR monocyte/lymphocyte; PLR = platelet/lymphocyte(24).

Ascertainment of covariates

Our study considered several covariates that could potentially influence the association between immune-inflammatory indexes and clinical LUTS, daytime LUTS, and nocturia. These covariates included age, race, education level, smoking status, alcohol use, body mass index (BMI, kg/m<sup>2</sup>), blood

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

121total cholesterol concentration, and history of hypertension and diabetes. Hypertension was defined as a122mean systolic blood pressure greater than 140 mmHg, or a mean diastolic blood pressure less than 90123mmHg, or a self-reported history of hypertension. Diabetes was defined as the use of antidiabetic124treatment, an HbA1c level of  $\geq 6.5\%$ , or a self-reported history of diabetes.

125 Statistical analysis

To obtain nationally representative findings for the men population aged 40 and over in the US, survey weights were included in the analysis in accordance with NHANES standards. Baseline feature indicators were presented as weighted mean and standard error (SE) for continuous data and weighted ratio for classified data. The difference between baseline characteristics was assessed using the student's t-test on continuous data and the Chi-square test on classified data. We used restricted cubic splines with three nodes at the 5th, 50th, and 95th percentiles to evaluate the nonlinear correlation between immune-inflammatory indexes and clinical LUTS, daytime LUTS and nocturia. Multivariate logistic regression was utilised in three models to explore the association between immune-inflammatory indexes and clinical LUTS, daytime LUTS and nocturia. Covariates were not adjusted in crude model, age, race, education level, smoking status, alcohol use, and BMI were adjusted in model 1, and model 2 was further adjusted for blood total cholesterol, and a history of diabetes and hypertension. Additionally, we conducted multivariate logistic ordinal regression analyses to verify the association of immune-inflammatory indexes with the number of positive symptoms associated with clinical LUTS (0, 1, 2, 3, 4). Furthermore, multiple logistics regression was used to explore whether there is a stronger correlation between SIRI + CRP, NLR + CRP, dNLR + CRP and clinical LUTS. Subgroup analyses were performed for the association between immune-inflammatory indexes and clinical LUTS, stratified by age, smoking, and a history of hypertension, and multiplicative interaction terms were used to test for interactions.

All statistical analyses were performed using R (version 4.2.2, http://www.r-project.org/).
Statistical significance was defined as a two-sided *P*-value < 0.05.</li>

146 Patient and public involvement

147 None.

148 RESULTS

- 149 Baseline characteristics
  - 150 As shown in Table 1, we included 2709 men participants aged 40 and above with complete

Page 7 of 34

# **BMJ** Open

 information, including 399 men who met the diagnostic criteria of clinical LUTS, 675 men who met the diagnostic criteria of daytime LUTS, and 946 men who had nocturia symptoms. Compared to men without clinical LUTS, men with clinical LUTS were older, less educated, smokers, and non-alcohol users, more prone to have lower blood cholesterol concentration, and higher hypertension, diabetes, PIV, SIRI, SII, NLR, dNLR and MLR values (all P < 0.05). Similarly, compared to men without daytime LUTS, men with daytime LUTS were older, non-alcohol users, more likely to have hypertension, diabetes, and higher PIV, SIRI, NLR, dNLR and MLR values (all P < 0.05). Furthermore, compared to men without nocturia, men with nocturia were found to be older, non-Hispanic Black, less educated, smokers, and non-alcohol users, more prone to have lower blood cholesterol concentration, and higher BMI, hypertension, diabetes, PIV, SIRI, NLR and MLR values (all P < 0.05). 

#### Dose-response relationships between immune-inflammatory indexes and LUTS

We used restricted cubic splines to assess the non-linear correlation between immune-inflammatory indexes and LUTS. After adjusting for covariates, we found that PIV, SIRI, SII, NLR, dNLR, MLR, and CRP had a linear relationship with clinical LUTS, daytime LUTS, and nocturia (all P for non-linearity > 0.05). Specifically, the prevalence of clinical LUTS increased by 14%, 22%, 16%, 24%, 21% and 21% per standard deviation of PIV, SIRI, SII, NLR, dNLR and CRP, respectively (all P <0.05) (Figure 1). The prevalence of daytime LUTS increased by 15%, 23%, 20%, and 15% per standard deviation of SIRI, NLR, dNLR and CRP, respectively (all P < 0.05) (Supplementary Figure 2). The prevalence of nocturia increased by 15%, 12%, 19%, and 23% per standard deviation of SIRI, NLR, MLR and CRP, respectively (all P < 0.05) (Supplementary Figure 3).

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### Multivariate logistic regression analyses between immune-inflammatory indexes and LUTS

To further clarify the relationship between immune-inflammatory indexes and LUTS, we classified each index into quartiles (Q1, Q2, Q3, Q4) and performed multiple logistic regression analyses with the Q1 group as reference. Our results showed that Q4 groups of PIV, SIRI, NLR, dNLR and CRP were positively correlated with clinical LUTS in all three models (all P < 0.05, all P for trend < 0.05). After adjustment for all confounders, PIV (OR = 1.60, 95% CI = 1.14-2.23), SIRI (OR = 1.82, 95% CI =1.21–2.73), NLR (*OR* = 1.81, 95% *CI* = 1.31–2.49), dNLR (*OR* = 1.91, 95% *CI* = 1.35–2.70), and CRP (OR = 1.71, 95 % CI = 1.05 - 2.79) in the Q4 group were significant risk factors for clinical LUTS in model 2. In the crude model, we also found that SII (OR = 1.45, 95% CI = 1.02-2.06) and MLR (OR = 1.02-2.06)

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

181 1.96, 95% CI = 1.17–3.28) in the Q4 group were positively correlated with LUTS (Table 2).
182 Furthermore, to confirm the linear relationship between these immune-inflammatory indexes and
183 LUTS, we conducted a multiple ordinal logistic regression analysis and found a significant positive
184 correlation between SIRI, SII, NLR, dNLR, MLR, and CRP and the number of positive symptoms
185 associated with clinical LUTS (Supplementary table 1).

Regarding the presence of daytime LUTS, we found a significant association between NLR (Q4, OR = 1.82, 95% CI = 1.21–2.74), dNLR (Q4, OR = 1.81, 95% CI = 1.20–2.71), and SIRI (Q4, OR = 1.82, 95% CI = 1.05–3.17) and increased risk of daytime LUTS (Supplementary table 2). By contrast, in the outcome of nocturia, MLR (Q4, OR = 1.49, 95% CI = 1.07–2.08) and CRP (Q4, OR = 1.59, 95% CI = 1.08-2.34) were significantly associated with nocturia (Supplementary table 3). Given the varying associations between immune-inflammatory indexes and different LUTS characteristics, we combined different indexes based on the results in Table 2. We selected cut-off values of 1.14, 2.08, 1.84, and 0.43 for SIRI, NLR, dNLR, and CRP, respectively, and divided them into high and low-level groups. We then combined SIRI, NLR, and dNLR with CRP in pairs to explore the correlation between the combined markers and clinical LUTS. The reference groups were the low CRP + low SIRI, low CRP + low NLR, and low CRP + low dNLR groups. As expected, when combined in pairs, the markers showed a stronger association with clinical LUTS than any single index alone, with the ORs for high SIRI + high CRP, high NLR + high CRP, and high dNLR + high CRP being 2.26 (95% CI = 1.56-3.26), 2.44 (95% CI = 1.60–3.71), and 2.16 (95% CI = 1.21-3.87), respectively, and there was a significant increasing trend for the prevalence of clinical LUTS (all P < 0.05) (Table 3).

201 Subgroup analyses

In our subgroup analyses, we examined the impact of age, smoking, and hypertension on the relationship between immune-inflammatory indexes and LUTS (Figure 2). Using the Q1 group as a reference, we found a more pronounced positive association between PIV, SIRI, SII, NLR, dNLR, MLR, CRP and clinical LUTS in older men aged 60 years and older in the Q4 group compared to those under 60 years (all P < 0.05, all P for interaction < 0.05). Similarly, smokers exhibited a stronger positive correlation between PIV, SIRI, NLR, CRP and clinical LUTS in the Q4 group than non-smokers (all P < 0.05, all P for interaction < 0.05). Additionally, hypertensive men in the Q4 group showed a significantly positive association between SIRI, NLR, dNLR and clinical LUTS than those without a history of hypertension (all P < 0.05, all P for interaction < 0.05). These findings suggested

that age, smoking, and hypertension might modify the impact of immune-inflammatory status onclinical LUTS and should be taken into consideration in clinical practice.

# 213 DISCUSSION

This study represents the first attempt to systematically investigate the association between different immune-inflammatory markers and LUTS risk, and to explore the potential effects of combining them. These findings revealed strong positive linear correlations between PIV, SIRI, NLR, dNLR, and CRP with clinical LUTS. Interestingly, when CRP was combined with SIRI, NLR, and dNLR respectively, the positive correlations with clinical LUTS became even stronger compared to any of the individual indexes alone. Additionally, subgroup analysis found that the effects of age, smoking, and history of hypertension varied in their influence on the relationship between immune-inflammatory indexes and clinical LUTS.

Previous studies have investigated the mechanisms underlying the association between inflammation and LUTS. As a common disease in aging men that can contribute to LUTS, the development and progression of BPH are closely related to prostatic inflammation(2, 3). In fact, Theyer et al. reported that human BPH tissue had a substantial influx of activated T cells, which secret various growth factors that facilitate prostate stromal and glandular hyperplasia(26). Additionally, stromal cells in BPH patients can stimulate the production of proinflammatory cytokines and chemotherapeutic kinases in a state of inflammation(27), such as IL-2, IL-4, IL-7, IL-17, and IFNy(28-30). Moreover, chronic inflammation in BPH is linked to the focal overexpression of cyclooxygenase 2 in the glandular epithelium, which results in the production of proinflammatory prostaglandins and prostate cell proliferation(27, 31). Furthermore, the pathogenesis of LUTS may involve different types of bladder dysfunction, such as detrusor overactivity or underactivity(2). There is a possible connection between inflammation and overactive bladder, which could be due to inflammation-induced remodelling of extracellular matrix and an increase in tissue stiffness(3). All the above studies have shown that there is a certain relationship between immune inflammation and LUTS.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

The risk of LUTS has been found to be associated with immune-inflammation indexes, which are readily available and inexpensive biomarkers. Although Rohrmann et al. did not find a positive correlation between CRP and LUTS using NHANESIII data(32), several studies revealed that an elevated level of CRP was related to an increased risk of LUTS(10-12, 33), consistent with our findings. The discrepancy in results may be due to differences in CRP classification criteria.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Additionally, previous small-scale studies have identified a link between elevated NLR levels and the progression of LUTS/BPH without performing multivariable analysis(13, 14). By contrast, our study provides strong evidence for a significant relationship between NLR and the prevalence of LUTS, regardless of whether NLR was treated as a continuous or categorical variable in multivariable regression analysis. Specially, we found that elevated levels of CPR were primarily associated with nocturia, while NLR, dNLR, and SIRI were associated with daytime LUTS. Given that previous studies have combined inflammatory markers to better reflect their relationship with disease(20-22), we attempted to combine CRP with NLR, dNLR, and SIRI. Our findings highlight a stronger linear correlation between the combination of these indexes and the risk of LUTS, indicating that composite immune-inflammation markers may be more effective in reflecting the risk of LUTS.

In our study, we discovered for the first time that several immune-inflammation biomarkers, namely PIV, SIRI, and dNLR, were positively correlated with the presence of clinical LUTS. Among these biomarkers, PIV stands out for its comprehensive nature, as it comprises peripheral blood counts of neutrophils, monocytes, lymphocytes, and platelets(18), making it a promising prognostic biomarker for various cancers(34). Similarly, SIRI and SII have been established as a prognostic indicator for different types of tumors(35-37) and inflammation-related diseases(38-40), as they reflect the balance between the immune response and inflammation. After adjusting for covariates, we found that SIRI was positively associated with LUTS while SII was not, which might be due to the weak relationship between platelets and LUTS. Among these pro-inflammatory cells, NLR has been the most extensively validated. However, dNLR, which replaces the denominator of NLR with (WBC-neutrophils), has emerged as an alternative in cases where lymphocyte information is unavailable(41). Proctor et al. found that both NLR and dNLR have equal reliability for the prognostic value in patients with cancer(41). Our study revealed a significant correlation between NLR and the prevalence of LUTS, as well as a comparable association between dNLR and LUTS. Since both indexes include neutrophils, it emphasises the strong and intimate link between neutrophils and LUTS, relative to other pro-inflammatory cells.

Subgroup analyses revealed that the positive association between inflammation and clinical LUTS
was stronger among the elderly, smokers, and hypertensive patients, highlighting the potential role of
excessive production and release of inflammatory factors in these populations, leading to increased
levels of inflammation(42-44). Additionally, factors such as physical aging, smoking, and hypertension

271 may contribute to a higher prevalence of LUTS through mechanisms such as prostate and bladder 272 aging, impaired renal function, and damage to blood vessels and nerves(45-47). Thus, it is important to 273 closely monitor the inflammation levels in these populations suffering from LUTS, and providing anti-274 inflammatory interventions for those with high inflammation levels might be a promising treatment 275 option.

This study has several advantages. Firstly, this is the first study to systematically explore the relationship between immune-inflammation indexes and LUTS, emphasising the importance of monitoring inflammation levels in individuals with LUTS. Secondly, the NHANES dataset comprises a representative sample of the national population, and we utilise NHANES-provided weights to ensure that our findings can be extrapolated to the broader population. Furthermore, multiple potential confounders were adjusted to ensure reliable results. However, this study also has several limitations. First, it is important to recognise that drawing causal conclusions from cross-sectional analyses presents challenges. Second, peripheral blood was tested only once rather than repeatedly, which may not accurately reflect a person's long-term peripheral blood status. Third, the questionnaire survey may have been subject to recall bias and reporting bias. Finally, the evaluation of LUTS relies on four questionnaire items from NHANES, which may not provide a thorough assessment of storage and voiding conditions, as well as the need for treatment.

288 CONCLUSIONS

In conclusion, this study emphasised that high levels of immune-inflammatory indexes such as PIV, SIRI, NLR, dNLR, and CRP were independent risk factors for clinical LUTS. The combination of CRP with SIRI, NLR, and dNLR respectively showed a stronger positive correlation with clinical LUTS compared to any of the individual indexes alone. Furthermore, the impact of age, smoking, and history of hypertension on the relationship between immune-inflammatory indexes and LUTS was significant. Further research, including multicentre studies, is needed to confirm the relationship between immune-inflammatory indexes and LUTS and to provide additional evidence for the management and treatment of clinical LUTS.

298 Acknowledgements

We appreciate the US Centers for Disease Control and Prevention for conducting the survey andmaking it available online freely, and all the participants for providing these data.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**Contributors** W-L: conceptualisation, methodology, data analysis, manuscript writing; J-W: methodology, data collection, data analysis, manuscript writing; MM-W: methodology, data collection, data analysis; M-W: data analysis, manuscript writing; X-D: methodology, supervision; M-L: conceptualisation, supervision, manuscript editing, funding acquisition. Funding This work was supported by the National Key Research and Development Program of China [2022YFC3602900] and Innovation Funds for Postgraduates of Peking Union Medical College [2021-I2M-1-050]. **Competing interests** None declared. Patient consent for publication Not applicable. **Ethical statement** Ethical review and approval for the research involving human participants were obtained from the Ethics Review Board of the NCHS (Protocol #98-12). Written informed consent was obtained from all patients or participants who were part of the study. The current analysis, which is based on publicly available data, did not necessitate any further ethics approval. Data availability statement Publicly available datasets were analysed in this study. This data can be downloaded from https://www.cdc.gov/nchs/nhanes/ (NHANES 2005-2006 and 2007-2008). References Fantus RJ, Packiam VT, Wang CH, Erickson BA, Helfand BT. The Relationship between Sleep Disorders and Lower Urinary Tract Symptoms: Results from the NHANES. J Urol. 2018;200(1):161-6. 2. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract

## **BMJ** Open

Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015;67(6):1099-109.

2	
3 4 5	329
6 7 8	330
9 10	331
11 12 13	332
14 15	333
16 17 18	334
19 20	335
21 22 23	336
24 25 26	337
20 27 28	338
29 30 31	339
32 33	340
34 35 36	341
37 38	342
39 40 41	343
42 43 44	344
45 46	345
47 48 49	346
50 51	347
52 53 54	348
55 56	349
57 58 59	350
60	

0 3. He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, Gupta S. Metabolic syndrome, 1 inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer 32 Prostatic Dis. 2016;19(1):7-13. 3 Bavendam TG, Norton JM, Kirkali Z, Mullins C, Kusek JW, Star RA, et al. Advancing a 4. 34 Comprehensive Approach to the Study of Lower Urinary Tract Symptoms. J Urol. 5 2016;196(5):1342-9. 6 5. Welliver C, Feinstein L, Ward JB, Fwu CW, Kirkali Z, Bavendam T, et al. Trends in Lower 37 Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the 8 Urologic Diseases in America Project. J Urol. 2020;203(1):171-8. 9 6. Cakir U, Tayman C, Tugcu AU, Yildiz D. Role of Systemic Inflammatory Indices in the -0 Prediction of Moderate to Severe Bronchopulmonary Dysplasia in Preterm Infants. Arch 1 Bronconeumol. 2023. 2 Cakir U, Tugcu AU, Tayman C, Yildiz D. Evaluation of the effectiveness of systemic 7. 3 inflammatory indices in the diagnosis of respiratory distress syndrome in preterm with 4 gestational age of ≤32 weeks. Am J Perinatol. 2023. -5 8. Wang RH, Wen WX, Jiang ZP, Du ZP, Ma ZH, Lu AL, et al. The clinical value of 6 neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-7 lymphocyte ratio (PLR) and systemic inflammation response index (SIRI) for predicting the 8 occurrence and severity of pneumonia in patients with intracerebral hemorrhage. Front 9 Immunol. 2023;14:1115031. 50 9. Erdogan A, Can FE, Gönüllü H. Evaluation of the prognostic role of NLR, LMR, PLR, and 1 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

351	LCR ratio in COVID-19 patients. J Med Virol. 2021;93(9):5555-9.
352	10. Kim JH, Doo SW, Yang WJ, Song YS, Kwon SS. Association Between High-sensitivity
353	C-reactive Protein and Lower Urinary Tract Symptoms in Healthy Korean Populations.
354	Urology. 2015;86(1):139-44.
355	11. St Sauver JL, Sarma AV, Jacobson DJ, McGree ME, Lieber MM, Girman CJ, et al.
356	Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract
357	symptom outcomes in a population-based cohort. Am J Epidemiol. 2009;169(11):1281-90.
358	12. Lu Z, Gao Y, Tan A, Yang X, Zhang H, Mo L, et al. Increased high-sensitivity C-reactive
359	protein predicts a high risk of lower urinary tract symptoms in Chinese male: Results from the
360	Fangchenggang Area Male Health and Examination Survey. Prostate. 2012;72(2):193-200.
361	13. Ozer K, Horsanali MO, Gorgel SN, Horsanali BO, Ozbek E. Association between Benign
362	Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and
363	Metabolic Syndrome. Urol Int. 2017;98(4):466-71.
364	14. Tanik S, Albayrak S, Zengin K, Borekci H, Bakirtas H, Imamoglu MA, et al. Is the
365	neutrophil-lymphocyte ratio an indicator of progression in patients with benign prostatic
366	hyperplasia? Asian Pac J Cancer Prev. 2014;15(15):6375-9.
367	15. Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of
368	Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE
369	PART I-Initial Work-up and Medical Management. J Urol. 2021;206(4):806-17.
370	16. Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, et al. Benign prostatic

**BMJ** Open

- 371 hyperplasia. Nat Rev Dis Primers. 2016;2:16031.
- 372 17. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation

BMJ Open

2		
3		
4	373	of terminology in lower urinary tract function: report from the standardisation sub-committee of
5		
6	074	the Internetional Continence Consists, Unclear, 2002-04/4)-27,40
7	374	the International Continence Society. Urology. 2003;61(1):37-49.
8		
9	375	18. Fucà G, Guarini V, Antoniotti C, Morano F, Moretto R, Corallo S, et al. The Pan-Immune-
10	010	
11		
12	376	Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results
13		
14	077	
15	377	from a pooled-analysis of the Valentino and TRIBE first-line trials. Br J Cancer.
16		
17	378	2020;123(3):403-9.
18	570	2020, 123(3).403-9.
19		
20	379	19. Jin Z, Wu Q, Chen S, Gao J, Li X, Zhang X, et al. The Associations of Two Novel
20		
22	380	Inflammation Indexes, SII and SIRI with the Risks for Cardiovascular Diseases and All-Cause
23		
24	381	Mortality: A Ten-Year Follow-Up Study in 85,154 Individuals. J Inflamm Res. 2021;14:131-40.
25	301	
26		
27	382	20. Abbate V, Barone S, Troise S, Laface C, Bonavolontà P, Pacella D, et al. The
28		
29		
30	383	Combination of Inflammatory Biomarkers as Prognostic Indicator in Salivary Gland
31		
32	201	Melignenay Concers (Basel) 2022:11(22)
	384	Malignancy. Cancers (Basel). 2022;14(23).
32 33 34	384	Malignancy. Cancers (Basel). 2022;14(23).
32 33		
32 33 34	384 385	Malignancy. Cancers (Basel). 2022;14(23). 21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory
32 33 34 35	385	21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory
32 33 34 35 36		
32 33 34 35 36 37	385	21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory
32 33 34 35 36 37 38	385 386	21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama.
32 33 34 35 36 37 38 39	385	21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory
32 33 34 35 36 37 38 39 40	385 386	21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama.
32 33 34 35 36 37 38 39 40 41	385 386	21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309(22):2353-61.
32 33 34 35 36 37 38 39 40 41 42	385 386 387	21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama.
32 33 34 35 36 37 38 39 40 41 42 43	385 386 387 388	<ul> <li>21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama.</li> <li>2013;309(22):2353-61.</li> <li>22. Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44	385 386 387	21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309(22):2353-61.
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	385 386 387 388	<ul> <li>21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama.</li> <li>2013;309(22):2353-61.</li> <li>22. Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47	385 386 387 388 389	<ul> <li>21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309(22):2353-61.</li> <li>22. Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48	385 386 387 388	<ul> <li>21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama.</li> <li>2013;309(22):2353-61.</li> <li>22. Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 43 44 45 46 47 48 49	385 386 387 388 389	<ul> <li>21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309(22):2353-61.</li> <li>22. Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50	385 386 387 388 389 390	<ul> <li>21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309(22):2353-61.</li> <li>22. Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic Marker of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. Front Oncol.</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51	385 386 387 388 389	<ul> <li>21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309(22):2353-61.</li> <li>22. Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52	385 386 387 388 389 390 391	<ol> <li>Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309(22):2353-61.</li> <li>Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic Marker of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. Front Oncol. 2019;9:914.</li> </ol>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53	385 386 387 388 389 390	<ul> <li>21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309(22):2353-61.</li> <li>22. Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic Marker of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. Front Oncol.</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54	385 386 387 388 389 390 391	<ol> <li>Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309(22):2353-61.</li> <li>Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic Marker of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. Front Oncol. 2019;9:914.</li> </ol>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	385 386 387 388 389 390 391 392	<ul> <li>21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309(22):2353-61.</li> <li>22. Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic Marker of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. Front Oncol. 2019;9:914.</li> <li>23. National Health and Nutrition Examination Survey. Available from:</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56	385 386 387 388 389 390 391	<ol> <li>Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309(22):2353-61.</li> <li>Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic Marker of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. Front Oncol. 2019;9:914.</li> </ol>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57	385 386 387 388 389 390 391 392	<ul> <li>21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309(22):2353-61.</li> <li>22. Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic Marker of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. Front Oncol. 2019;9:914.</li> <li>23. National Health and Nutrition Examination Survey. Available from:</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58	385 386 387 388 389 390 391 392	<ul> <li>21. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309(22):2353-61.</li> <li>22. Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic Marker of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. Front Oncol. 2019;9:914.</li> <li>23. National Health and Nutrition Examination Survey. Available from:</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57	385 386 387 388 389 390 391 392 393	<ol> <li>Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309(22):2353-61.</li> <li>Zheng Y, Chen Y, Chen J, Chen W, Pan Y, Bao L, et al. Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic Marker of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. Front Oncol. 2019;9:914.</li> <li>National Health and Nutrition Examination Survey. Available from: https://www.cdc.gov/nchs/nhanes/ [Accessed March 23, 2023 pp.].</li> </ol>

Page 16 of 34

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**BMJ** Open

inflammation and low performance status with reduced survival outcome in older adults withcancer. Clin Nutr. 2022;41(10):2284-94.

397 25. Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of

the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients

399 With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018;4(3):351-7.

- 400 26. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, et al.
  401 Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab
  402 Invest. 1992;66(1):96-107.
- 403 27. Chughtai B, Lee R, Te A, Kaplan S. Inflammation and benign prostatic hyperplasia: 404 clinical implications. Curr Urol Rep. 2011;12(4):274-7.
- 405 28. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an
  406 immune inflammatory disease? Eur Urol. 2007;51(5):1202-16.
- 407 29. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, et al. Increased
  408 expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue,
  409 identification of the producing cell types, and effect of differentially expressed cytokines on
  410 stromal cell proliferation. Prostate. 2002;52(1):43-58.
  - 411 30. Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, Reithmayr F, et al. Cytokine
  - 412 expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic
  - 413 infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest. 2003;83(8):1131-46.
  - 414 31. Kaplan SA. Chronic Inflammation in Benign Prostate Hyperplasia is Associated With
- 415 Focal Upregulation of Cyclooxygenase-2, Bcl-2, and Cell Proliferation in the Glandular
- 416 Epithelium. J Urol. 2005;173(4):1266-7.

**BMJ** Open

32. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate. 2005;62(1):27-33. 33. Hung SF, Chung SD, Kuo HC. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. PLoS One. 2014;9(1):e85588. 34. Guven DC, Sahin TK, Erul E, Kilickap S, Gambichler T, Aksoy S. The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022;14(11). 35. Meng L, Yang Y, Hu X, Zhang R, Li X. Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis. J Transl Med. 2023;21(1):79. 36. Cao Y, Zheng X, Hu Y, Li J, Huang B, Zhao N, et al. Levels of systemic inflammation response index are correlated with tumor-associated bacteria in colorectal cancer. Cell Death Dis. 2023;14(1):69. 37. Zhang S, Du J, Zhong X, Tan P, Xu H, Zhang J, et al. The prognostic value of the systemic immune-inflammation index for patients with bladder cancer after radical cystectomy. Front Immunol. 2022;13:1072433. 38. Biyik M, Biyik Z, Asil M, Keskin M. Systemic Inflammation Response Index and Systemic Immune Inflammation Index Are Associated with Clinical Outcomes in Patients with Acute Pancreatitis? J Invest Surg. 2022;35(8):1613-20. Huang YW, Yin XS, Li ZP. Association of the systemic immune-inflammation index (SII)

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**BMJ** Open

439 and clinical outcomes in patients with stroke: A systematic review and meta-analysis. Front
440 Immunol. 2022;13:1090305.

441 40. Song Y, Guo W, Li Z, Guo D, Li Z, Li Y. Systemic immune-inflammation index is
442 associated with hepatic steatosis: Evidence from NHANES 2015-2018. Front Immunol.
443 2022;13:1058779.

444 41. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived
445 neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer.
446 2012;107(4):695-9.

447 42. Liberale L, Badimon L, Montecucco F, Lüscher TF, Libby P, Camici GG. Inflammation,
448 Aging, and Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol.
449 2022;79(8):837-47.

450 43. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular
451 disease: an update. J Am Coll Cardiol. 2004;43(10):1731-7.

452 44. Mouton AJ, Li X, Hall ME, Hall JE. Obesity, Hypertension, and Cardiac Dysfunction:

453 Novel Roles of Immunometabolism in Macrophage Activation and Inflammation. Circ Res.

454 2020;126(6):789-806.

455 45. Kim EH, Larson JA, Andriole GL. Management of Benign Prostatic Hyperplasia. Annu

456 Rev Med. 2016;67:137-51.

- 457 46. Matzkin H, Soloway MS. Cigarette smoking: a review of possible associations with
  458 benign prostatic hyperplasia and prostate cancer. Prostate. 1993;22(4):277-90.
- 459 47. Gacci M, Corona G, Sebastianelli A, Serni S, De Nunzio C, Maggi M, et al. Male Lower
- 460 Urinary Tract Symptoms and Cardiovascular Events: A Systematic Review and Meta-analysis.

# 461 Eur Urol. 2016;70(5):788-96.

**Figure legends** 

Figure 1. Dose-response relationships between blood immune-inflammatory indexes and clinical LUTS (A) PIV and clinical LUTS; (B) SIRI and LUTS; (C) SII and LUTS; (D) NLR and LUTS; (E) dNLR and LUTS; (F) MLR and LUTS; (G) PLR and LUTS; (H) CRP and LUTS. They are adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI, total cholesterol, and a history of diabetes and hypertension. The shaded part represents the 95% CI. Abbreviations: OR, odds ratio; LUTS, lower urinary tract symptoms; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein.

Figure 2. Associations between blood immune-inflammatory indexes and clinical LUTS in subgroup
analyses. They are adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and
BMI, total cholesterol, and a history of diabetes and hypertension, if not already stratified.
Abbreviations: OR, odds ratio; LUTS, lower urinary tract symptoms; PIV, pan-immune-inflammation
value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR,
neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to
lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein.

482 Supplementary Figure 1. Study flowchart. Of 20,497 participants in the 2005–2008 National Health
483 and Nutrition Examination Survey (NHANES), 2,709 remained after fulfilling inclusion and exclusion
484 criteria

Supplementary Figure 2. Dose-response relationships between blood immune-inflammatory indexes and daytime LUTS (A) PIV and LUTS; (B) SIRI and LUTS; (C) SII and LUTS; (D) NLR and LUTS; (E) dNLR and LUTS; (F) MLR and LUTS; (G) PLR and LUTS; (H) CRP and LUTS. They are adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI, total cholesterol, and a history of diabetes and hypertension. The shaded part represents the 95% CI. Abbreviations: OR, odds ratio; LUTS, lower urinary tract symptoms; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein.

Supplementary Figure 3. Dose-response relationships between blood immune-inflammatory indexes and nocturia (A) PIV and LUTS; (B) SIRI and LUTS; (C) SII and LUTS; (D) NLR and LUTS; (E) dNLR and LUTS; (F) MLR and LUTS; (G) PLR and LUTS; (H) CRP and LUTS. They are adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI, total cholesterol, and a history of diabetes and hypertension. The shaded part represents the 95% CI. Abbreviations: OR, odds ratio; LUTS, lower urinary tract symptoms; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; 504 PLR, platelet to lymphocyte ratio; CRP, C-reactive protein.

 Table 1. Demographic and clinic characteristics according to clinical LUTS, daytime LUTS, and nocturia. NHANES 2005-2008\*

Ch	Total	Clinica	I LUTS		Daytim	e LUTS	-	Noc	turia	_
Characterist ics	Adults (N = 2709)	No (N = 2310)	Yes (N = 399)	<i>P</i> value	No (N = 2034)	Yes (N = 675)	<i>P</i> value	No (N = 1763)	Yes (N = 946)	<i>P</i> valu
Age, years,				<			<		· · ·	<
n (%) < 60	1362(64. 90) 1347(35.	1240(67. 84) 1070(32.	122(43.4 6) 277(56.5	0.01	1110(68. 60) 924(31.4	252(52.0 9) 423(47.9	0.01	1045(72. 17) 718(27.8	317(44.8 8) 629(55.1	0.01
≥60	10)	16)	4)		0)	1)		3)	2)	
Race/ethnici ty, n (%) Non-				0.94			0.67			< 0.01
Hispanic White	1502(78. 06)	1261(77. 96)	241(78.7 7)		1108(77. 87)	394(78.7 1)		1003(80. 02)	499(72.6 3)	
Non- Hispanic Black	508(8.82 )	435(8.90 )	73(8.22)		388(9.15 )	120(7.66 )		298(7.34 )	210(12.8 8)	
Mexican	433(6.14 )	379(6.19 )	54(5.81)		334(6.24 )	99(5.81)		272(5.46	161(8.03 )	
Other	266(6.99 )	235(6.96 )	31(7.20)		204(6.75 )	62(7.83)		190(7.18 )	76(6.46)	
Education, n (%)				< 0.01			0.08			< 0.01
Grades 0–12	821(17.8 0)	675(16.7 3)	146(25.6 3)		599(16.8 5)	222(21.1 0)		460(14.5 0)	361(26.8 9)	
High school graduate/GE D	651(25.6 1)	555(25.5 3)	96(26.19 )		487(25.2 2)	164(26.9 8)		433(25.7 5)	218(25.2 3)	
Some college or above	1237(56. 59)	1080(57. 74)	157(48.1 8)		948(57.9 4)	289(51.9 1)		870(59.7 5)	367(47.8 8)	
Smoking†, n (%)	1(01/50	1200(57	201/72.0	< 0.01	1007(59	154(62.1	0.06	102((55	(15)(0.2	< 0.01
Yes	1681(59. 25) 1028(40.	1390(57. 37) 920(42.6	291(72.9 9) 108(27.0		1227(58. 41) 807(41.5	454(62.1 8) 221(37.8		1036(55. 58) 727(44.4	645(69.3 7) 301(30.6	
No Alcohol use <sup>‡</sup> ,	75)	3)	1)	<	9)	2)	<	2)	3)	<
n (%)				0.01			0.01			0.01
Yes	1776(72. 69) 933(27.3	1550(74. 51) 760(25.4	226(59.4 1) 173(40.5		1376(75. 21) 658(24.7	400(63.9 8) 275(36.0		1213(75. 41) 550(24.5	563(65.2 0) 383(34.8	
No	955(27.5 1)	9)	9)		9)	275(50.0		9)	0)	
BMI <sup>§</sup> , kg/m <sup>2</sup> , n (%)				0.94			0.83			0.02
< 25	627(21.5 3)	527(21.4 2)	100(22.2 9)		463(21.2 5)	164(22.4 7)		397(21.7 8)	230(20.8 2)	
25–29.9	1139(43. 17) 943(35.3	982(43.1 4) 801(35.4	157(43.4 2) 142(34.2		863(43.0 3) 708(35.7	276(43.6 5) 235(33.8		783(45.1 9) 583(33.0	356(37.6 1) 360(41.5	
$\geq$ 30	943(55.5 0)	4)	9)		1)	8)		3)	7)	
Total cholesterol, mmol/L, n (%)				0.02			0.38			< 0.01
< 5.02	1370(47. 14)	1137(46. 02)	233(55.3 1)		1006(46. 51)	364(49.3 1)		833(44.2 2)	537(55.1 8)	
≥ 5.02	1339(52. 86)	1173(53. 98)	166(44.6 9)		1028(53. 49)	311(50.6 9)		930(55.7 8)	409(44.8 2)	
Hypertensio n, n (%)	,	,	,	< 0.01	,	,	< 0.01	,	,	< 0.01
Yes	1441(49. 14) 1268(50.	1188(47. 25) 1122(52.	253(62.9 3) 146(37.0		1029(46. 53) 1005(53.	412(58.2 0) 263(41.8		833(44.0 0) 930(56.0	608(63.3 2) 338(36.6	
No	1208(50. 86)	75)	140(37.0 7)		47)	203(41.8 0)		930(30.0 0)	8)	
Diabetes, n				<			0.01			<

1	
2	
3	
4	
5	
6 7	
7	
8	
9	
10	
11	
11	
12	
13	
14	
15	
16	
16 17	
1/	
18	
19	
20	
21	
22 23	
22	
23	
24	
25	
26 27	
27	
28	
28 29	
29	
30	
31	
32	
33	
34	
54	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
45	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
50	

Yes	558(15.1 6) 2151(84.	453(13.9 3) 1857(86.	105(24.1 7) 294(75.8		395(13.5 4) 1639(86.	163(20.7 8) 512(79.2		292(11.9 7) 1471(88.	266(23.9 7) 680(76.0	
No	2131(84. 84)	1837(80. 07)	294(75.8 3)		46)	2)		03)	3)	
WBC, 1000 cells/ul, mean (SE)	7.28(0.0 7)	7.22(0.0 7)	7.74(0.1 8)	0.01	7.25(0.0 8)	7.41(0.1 1)	0.22	7.25(0.0 8)	7.38(0.1 2)	0.41
Neu, 1000 cells/ul, mean (SE)	4.36(0.0 5)	4.31(0.0 6)	4.72(0.0 9)	< 0.01	4.31(0.0 6)	4.51(0.0 8)	0.05	4.33(0.0 7)	4.42(0.0 8)	0.38
Lym, 1000 cells/ul, mean (SE)	2.07(0.0 3)	2.07(0.0 2)	2.13(0.1 2)	0.63	2.09(0.0 3)	2.03(0.0 7)	0.41	2.08(0.0 2)	2.06(0.0 6)	0.83
Mono, 1000 cells/ul, mean (SE)	0.59(0.0 1)	0.59(0.0 1)	0.62(0.0 2)	0.06	0.59(0.0 1)	0.59(0.0 1)	0.51	0.58(0.0 1)	0.61(0.0 1)	0.02
PLT, 1000 cells/ul, mean (SE)	252.30(1 .74)	253.68(1 .92)	242.25(3 .78)	0.01	254.55(1 .70)	244.53(3 .97)	0.02	255.35(2 .23)	243.91(2 .51)	< 0.01
CRP, mg/dl, mean (SE)	0.38(0.0 2)	0.35(0.0 2)	0.63(0.1 4)	0.06	0.35(0.0 2)	0.51(0.0 8)	0.06	0.32(0.0 1)	0.55(0.0 8)	0.01
PIV, mean (SE)	352.79(8 .51)	345.11(8 .45)	408.87(1 8.25)	< 0.01	345.06(9 .09)	379.59(1 4.17)	0.02	342.07(8 .07)	382.35(1 4.59)	< 0.01
SIRI, mean (SE)	1.38(0.0 3)	1.34(0.0	1.66(0.0	< 0.01	1.33(0.0	1.53(0.0	< 0.01	1.32(0.0	1.53(0.0	<
(SE) SII, mean (SE)	5) 586.41(1 0.55)	3) 577.92(1 1.21)	6) 648.46(2 5.42)	0.01	3) 575.69(1 2.23)	4) 623.61(2 0.14)	0.01	3) 578.16(1 1.65)	5) 609.18(1 6.11)	0.01 0.08
NLR, mean	2.32(0.0	2.27(0.0	2.67(0.0	<	2.25(0.0	2.56(0.0	<	2.26(0.0	2.47(0.0	<
(SE)	4)	4)	8)	0.01	4)	7)	0.01	4)	5)	0.01
dNLR, maan (SF)	1.58(0.0	1.55(0.0)	1.73(0.0	<	1.54(0.0)	1.69(0.0)	<	1.56(0.0)	1.62(0.0)	0.08
mean (SE) MLR, mean	2) 0.31(0.0	2) 0.31(0.0	4) 0.34(0.0	0.01	2) 0.30(0.0	3) 0.33(0.0	0.01 <	2) 0.30(0.0	3) 0.34(0.0	<
(SE)	0.51(0.0	0.51(0.0	1)	0.01	0.30(0.0	1)	0.01	0.30(0.0	1)	0.01
PLR, mean	134.99(1	134.75(1	136.73(4	0.67	133.75(1	139.26(4	0.24	134.33(1	136.79(2	0.45

Abbreviations: LUTS, lower urinary tract symptoms NHANES, National Health and Nutrition Examination Survey; SE, standard error; GED, General Equivalency Diploma; BMI, body mass index; WBC, leukocyte; Neu, neutrophil; Lym, lymphocyte; Mono, monocyte; PLT, platelet; CRP, C-reactive protein; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio.

\*Means and percentages were adjusted for survey weights of NHANES.

\*Smoking was defined as smoking at least 100 cigarettes during their lifetime.

‡Alcohol use was defined as having at least 12 alcohol drinks in any given year.

BMI was calculated by dividing weight in kilograms (kg) by height in meters squared (m<sup>2</sup>). Participants were classified as normal weight (< 25 kg/m<sup>2</sup>), overweight (25–29.9 kg/m<sup>2</sup>), and obese ( $\geq$  30 kg/m<sup>2</sup>).

# 507 508

Table 2. OR (95% CI) for LUTS across quartiles of blood immune-inflammatory indexes\*

	Crude Model	P value	Model 1	P value	Model 2	P value
PIV						
Q1 (< 181.50)	1[Reference]		1[Reference]		1[Reference]	
Q2 (181.50–276.64)	1.15(0.73,1.80)	0.53	1.11(0.69,1.79)	0.65	1.14(0.71,1.85)	0.56
Q3 (276.65–421.83)	0.86(0.59,1.24)	0.39	0.79(0.54,1.17)	0.22	0.82(0.57,1.18)	0.26
Q4 (≥ 421.84)	1.85(1.34,2.56)	< 0.01	1.59(1.14,2.24)	0.01	1.60(1.14,2.23)	0.01
P for trend		< 0.01		0.01		0.02
SIRI						
Q1 (< 0.80)	1[Reference]		1[Reference]		1[Reference]	
Q2 (0.80–1.14)	1.01(0.58,1.73)	0.98	0.98(0.56,1.70)	0.93	0.97(0.55,1.72)	0.92
Q3 (1.15–1.65)	1.39(1.06,1.84)	0.02	1.26(0.94,1.69)	0.12	1.23(0.91,1.66)	0.17
Q4 (≥ 1.66)	2.35(1.61,3.44)	< 0.01	1.91(1.30,2.82)	< 0.01	1.82(1.21,2.73)	0.01
P for trend		< 0.01		< 0.01		< 0.01
SII						
Q1 (< 356.13)	1[Reference]		1[Reference]		1[Reference]	

Q2 (356.13–500.41)	0.97(0.68,1.39)	0.86	0.97(0.65,1.43)	0.86	1.02(0.71,1.48)	0.89
Q3 (500.42–702.31)	0.98(0.67,1.43)	0.91	1.00(0.66,1.51)	0.99	1.04(0.71,1.54)	0.82
Q4 (≥ 702.32)	1.45(1.02,2.06)	0.04	1.37(0.94,2.00)	0.09	1.40(0.97,2.04)	0.07
<i>P</i> for trend		< 0.01		0.03		0.03
NLR						
Q1 (< 1.56)	1[Reference]		1[Reference]		1[Reference]	
Q2 (1.56–2.08)	1.08(0.74,1.60)	0.67	1.15(0.76,1.75)	0.50	1.16(0.75,1.80)	0.48
Q3 (2.09–2.72)	1.75(1.16,2.63)	0.01	1.73(1.12,2.66)	0.02	1.71(1.10,2.66)	0.02
Q4 (≥ 2.73)	2.21(1.60,3.04)	< 0.01	1.89(1.39,2.56)	< 0.01	1.81(1.31,2.49)	< 0.01
P for trend		< 0.01		< 0.01		< 0.01
dNLR						
Q1 (< 1.13)	1[Reference]		1[Reference]		1[Reference]	
Q2 (1.13–1.44)	1.09(0.80,1.49)	0.55	1.09(0.80,1.50)	0.56	1.10(0.80,1.51)	0.55
Q3 (1.45–1.84)	1.32(0.92,1.89)	0.12	1.32(0.92,1.89)	0.12	1.33(0.92,1.90)	0.12
Q4 (≥ 1.85)	2.17(1.55,3.04)	< 0.01	1.98(1.42,2.77)	< 0.01	1.91(1.35,2.70)	< 0.01
P for trend		< 0.01		< 0.01		< 0.01
MLR						
Q1 (< 0.22)	1[Reference]		1[Reference]		1[Reference]	
Q2 (0.22–0.29)	1.27(0.72,2.24)	0.39	1.24(0.69,2.25)	0.45	1.25(0.69,2.27)	0.43
Q3 (0.30–0.37)	1.49(0.87,2.56)	0.14	1.38(0.79,2.41)	0.24	1.38(0.77,2.46)	0.26
Q4 (≥ 0.38)	1.96(1.17,3.28)	0.01	1.51(0.89,2.57)	0.12	1.44(0.82,2.53)	0.18
P for trend		< 0.01		0.09		0.16
PLR						
Q1 (< 97.90)	1[Reference]		1[Reference]		1[Reference]	
Q2 (97.90–124.74)	0.94(0.59,1.49)	0.79	0.97(0.61,1.55)	0.90	1.00(0.62,1.62)	0.98
Q3 (124.75–159.41)	0.70(0.49,0.99)	0.04	0.81(0.56,1.18)	0.26	0.86(0.58,1.27)	0.41
Q4 (≥ 159.42)	1.09(0.72,1.63)	0.68	1.09(0.73,1.64)	0.65	1.14(0.74,1.74)	0.53
P for trend		0.77		0.70		0.57
CRP, mg/dl						
Q1 (< 0.09)	1[Reference]		1[Reference]		1[Reference]	
Q2 (0.09–0.20)	0.88(0.56,1.38)	0.57	0.84(0.53,1.34)	0.45	0.83(0.51,1.34)	0.41
Q3 (0.21–0.43)	1.12(0.66,1.92)	0.66	1.05(0.59,1.88)	0.86	1.05(0.58,1.88)	0.87
Q4 (≥ 0.43)	2.03(1.28,3.22)	< 0.01	1.78(1.09,2.90)	0.02	1.71(1.05,2.79)	0.03
<i>P</i> for trend	~ / /	< 0.01	. , ,	< 0.01	,	< 0.01

Abbreviations: *OR*, odds ratio; *CI*, confidence interval; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein. \*Values are numerical values or weighted *OR* (95% *CI*).

Model 1 was adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI.

Model 2 was additionally adjusted for total cholesterol, and a history of diabetes and hypertension.

Table 3. OR (95% CI) for clinical LUTS across combined blood immune-inflammatory indexes\*

	Crude Model	P value	Model 1	P value	Model 2	P value			
SIRI+CRP (Low SIRI < 1.14, High SIRI $\ge$ 1.14; Low CRP < 0.43, High CRP $\ge$ 0.43)									
Low SIRI and Low CRP	1[Reference]		1[Reference]		1[Reference]				
High SIRI and Low CRP	1.83(1.34,2.50)	< 0.01	1.60(1.13,2.25)	0.01	1.56(1.10,2.21)	0.02			
Low SIRI and High CRP	2.28(1.28,4.07)	0.01	2.15(1.12,4.14)	0.02	2.10(1.09,4.03)	0.03			
High SIRI and High CRP	2.90(2.04,4.12)	< 0.01	2.39(1.65,3.48)	< 0.01	2.26(1.56,3.26)	< 0.01			


NLR+CRP (Low NLR < 2.	08, High NLR $\geq$ 2.0	8)				
Low NLR and Low CRP	1[Reference]		1[Reference]		1[Reference]	
High NLR and Low CRP	2.06(1.54,2.77)	< 0.01	1.82(1.37,2.41)	< 0.01	1.78(1.33,2.38)	< 0.01
Low NLR and High CRP	2.69(1.57,4.62)	< 0.01	2.40(1.33,4.32)	0.01	2.31(1.29,4.14)	0.01
High NLR and High CRP	3.07(2.11,4.46)	< 0.01	2.59(1.73,3.86)	< 0.01	2.44(1.60,3.71)	< 0.01
dNLR+CRP (Low dNLR <	1.84, High dNLR	≥ 1.84)				
Low dNLR and Low CRP	1[Reference]		1[Reference]		1[Reference]	
High dNLR and Low CRP	2.03(1.39,2.97)	< 0.01	1.88(1.24,2.84)	< 0.01	1.87(1.22,2.87)	0.01
Low dNLR and High CRP	2.16(1.37,3.41)	< 0.01	2.01(1.23,3.26)	0.01	1.99(1.23,3.23)	0.01
High dNLR and High CRP	2.84(1.66,4.87)	< 0.01	2.38(1.35,4.21)	< 0.01	2.16(1.21,3.87)	0.01

Abbreviations: OR, odds ratio; CI, confidence interval; SIRI, system inflammation response index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; CRP, C-reactive protein.

\*Values are numerical values or weighted OR (95% CI).

Model 1 was adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI.

Model 2 was additionally adjusted for total cholesterol, and a history of diabetes and hypertension.



539x488mm (300 x 300 DPI)

Markers	Age < 60 years OR (95%Cl)	Age > 60 years OR (95%Cl)	Smoking (No) OR (95%Cl)	Smoking (Yes) OR (95%Cl)	Hypertension (No) OR (95%Cl)	Hypertension (Yes OR (95%CI)
PIV						
Q2 VS Q1	· · · · · · · · · · · · · · · · · · ·	<b></b>	<b>→</b>	<b>—</b>	<u>⊢.</u>	
Q3 VS Q1	Here a				H	
Q4 VS Q1						
SIRI	:		:	:	:	:
Q2 VS Q1	H	<b>—</b>				<b>—</b>
Q3 VS Q1		· · · · · · · · · · · · · · · · · · ·				
Q4 VS Q1		·→				
SII	:	:	:	:	:	:
Q2 VS Q1	H H		H H	<b>H</b>		<b>H</b>
Q3 VS Q1	H	<b>H</b>				<b>H</b>
Q4 VS Q1					· · · · · · · · · · · · · · · · · · ·	
NLR	:	:	:	:	:	:
Q2 VS Q1	H					
Q3 VS Q1		<b>→</b>				
Q4 VS Q1		→ → →			· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·
dNLR	:	:	:	:	:	:
Q2 VS Q1		H-H-H		<b>H</b>	H-1	
Q3 VS Q1						
Q4 VS Q1	i i i i i i i i i i i i i i i i i i i	$\mapsto$	· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·	
MLR	:	:	:	:	:	:
Q2 VS Q1	<b>—</b>			H-H-H-H-H-H-H-H-H-H-H-H-H-H-H-H-H-H-H-		<b>—</b>
Q3 VS Q1						
Q4 VS Q1				· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	
PLR	:	:	:	:	:	:
Q2 VS Q1		<b></b>				<b>—</b>
Q3 VS Q1	H	<b>—</b>	H			
Q4 VS Q1	<b></b>					
CRP	:	:	:	:	:	:
Q2 VS Q1			++			
Q3 VS Q1	H		H		H	H-1
Q4 VS Q1						
	20.5 1 2 3 3.	5 0.5 1 2 3 3.5	50.2 0.5 1 2 3 3		.50.2 0.5 1 2 3 3.	5 0.5 1 2

Fig. 2 Associations between blood immune-inflammatory indexes and clinical LUTS in subgroup analyses. They are adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI, total cholesterol, and a history of diabetes and hypertension, if not already stratified. Abbreviations: OR, odds ratio; LUTS, lower urinary tract symptoms; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein.

311x220mm (300 x 300 DPI)

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1								
	Crude Model	P value	Model 1	P value	Model 2	P value		
PIV	1.15(1.06,1.24)	< 0.01	1.10(1.02,1.19)	0.02	1.08(1.00,1.18)	0.06		
SIRI	1.27(1.17,1.37)	< 0.01	1.18(1.09,1.28)	< 0.01	1.16(1.06,1.26)	< 0.01		
SII	1.13(1.03,1.24)	0.01	1.12(1.02,1.22)	0.02	1.10(1.01,1.21)	0.03		
NLR	1.28(1.15,1.42)	< 0.01	1.22(1.11,1.34)	< 0.01	1.20(1.10,1.32)	< 0.01		
dNLR	1.18(1.06,1.31)	< 0.01	1.16(1.06,1.28)	< 0.01	1.15(1.05,1.25)	< 0.01		
MLR	1.27(1.17,1.37)	< 0.01	1.17(1.06,1.28)	< 0.01	1.16(1.05,1.27)	< 0.01		
PLR	1.09(1.06,1.24)	< 0.01	1.09(0.98,1.20)	0.10	1.10(1.00,1.22)	0.06		
CRP, mg/dl	1.20(1.13,1.27)	< 0.01	1.20(1.13,1.26)	< 0.01	1.19(1.12,1.27)	< 0.01		

**Supplementary table 1.** Multivariate logistic ordinal regression analysis of the blood immune-inflammatory indexes among the number of positive symptoms associated with clinical LUTS<sup>\*</sup>

Abbreviations: *OR*, odds ratio; *CI*, confidence interval; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein. \*Values are numerical values or weighted *OR* (95% *CI*).

Model 1 was adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI;

Model 2 was additionally adjusted for total cholesterol, and a history of diabetes and hypertension.

# **BMJ** Open

	Crude Model	P value	Model 1	P value	Model 2	P valu
PIV						
Q1 (< 181.50)	1[Reference]		1[Reference]		1[Reference]	
Q2 (181.50–276.64)	1.20(0.83,1.71)	0.32	1.16(0.79,1.69)	0.44	1.17(0.80,1.71)	0.39
Q3 (276.65–421.83)	0.95(0.65,1.40)	0.81	0.91(0.62,1.34)	0.62	0.93(0.63,1.35)	0.67
Q4 (≥ 421.84)	1.46(0.96,2.21)	0.07	1.33(0.87,2.03)	0.17	1.32(0.85,2.03)	0.20
P for trend		0.07		0.16		0.22
SIRI						
Q1 (< 0.80)	1[Reference]		1[Reference]		1[Reference]	
Q2 (0.80–1.14)	1.08(0.62,1.88)	0.77	1.05(0.60,1.86)	0.85	1.04(0.58,1.86)	0.88
Q3 (1.15–1.65)	1.14(0.76,1.71)	0.51	1.05(0.68,1.62)	0.81	1.01(0.66,1.57)	0.94
Q4 (≥ 1.66)	1.82(1.05,3.17)	0.03	1.59(0.89,2.85)	0.11	1.52(0.83,2.80)	0.16
P for trend		< 0.01		0.04		0.07
SII						
Q1 (< 356.13)	1[Reference]		1[Reference]		1[Reference]	
Q2 (356.13–500.41)	1.00(0.72,1.39)	0.99	0.99(0.69,1.42)	0.96	1.03(0.73,1.45)	0.86
Q3 (500.42–702.31)	1.03(0.71,1.49)	0.86	1.02(0.70,1.51)	0.90	1.05(0.71,1.54)	0.81
Q4 (≥ 702.32)	1.32(0.89,1.95)	0.16	1.27(0.84,1.93)	0.25	1.28(0.83,1.96)	0.24
P for trend		0.11		0.17		0.19
NLR						
Q1 (< 1.56)	1[Reference]		1[Reference]		1[Reference]	
Q2 (1.56–2.08)	1.18(0.92,1.52)	0.19	1.19(0.90,1.57)	0.20	1.18(0.89,1.58)	0.23
Q3 (2.09–2.72)	1.41(0.91,2.18)	0.12	1.34(0.85,2.10)	0.19	1.32(0.83,2.09)	0.22
Q4 (≥ 2.73)	2.10(1.44,3.05)	< 0.01	1.87(1.26,2.78)	< 0.01	1.82(1.21,2.73)	0.01
P for trend		< 0.01		< 0.01		< 0.01
dNLR						
Q1 (< 1.13)	1[Reference]		1[Reference]		1[Reference]	
Q2 (1.13–1.44)	1.25(0.98,1.61)	0.07	1.23(0.95,1.59)	0.11	1.23(0.95,1.59)	0.11
Q3 (1.45–1.84)	1.20(0.78,1.83)	0.39	1.15(0.74,1.78)	0.51	1.15(0.74,1.79)	0.51
Q4 (≥ 1.85)	1.99(1.35,2.93)	< 0.01	1.86(1.25,2.75)	< 0.01	1.81(1.20,2.71)	0.01
P for trend		< 0.01		< 0.01		0.01
MLR						
Q1 (< 0.22)	1[Reference]		1[Reference]		1[Reference]	
Q2 (0.22–0.29)	1.17(0.81,1.69)	0.38	1.13(0.77,1.66)	0.50	1.13(0.77,1.66)	0.49
Q3 (0.30–0.37)	1.32(0.85,2.06)	0.20	1.23(0.77,1.96)	0.36	1.22(0.75,1.98)	0.40
Q4 (≥ 0.38)	1.66(1.14,2.42)	0.01	1.38(0.93,2.04)	0.10	1.35(0.89,2.03)	0.15
P for trend		0.01		0.13		0.19
PLR						
Q1 (< 97.90)	1[Reference]		1[Reference]		1[Reference]	
Q2 (97.90–124.74)	0.92(0.65,1.30)	0.63	0.93(0.66,1.32)	0.68	0.94(0.66,1.34)	0.71
Q3 (124.75–159.41)	0.76(0.60,0.96)	0.02	0.81(0.64,1.04)	0.09	0.83(0.65,1.07	0.14
Q4 (≥159.42)	1.13(0.82,1.57)	0.44	1.11(0.80,1.55)	0.50	1.13(0.80,1.60)	0.45
P for trend		0.47		0.52		0.45
CRP, mg/dl						
Q1 (< 0.09)	1[Reference]		1[Reference]		1[Reference]	

Q2 (0.09-0.20) $0.84(0.62,1.15)$ $0.28$ $0.83(0.59,1.16)$ $0.26$ $0.82(0.58,1.16)$ $0.23$ Q3 (0.21-0.43) $0.95(0.66,1.37)$ $0.79$ $0.95(0.64,1.39)$ $0.76$ $0.92(0.63,1.36)$ $0.66$ Q4 ( $\geq 0.43$ ) $1.36(0.97,1.91)$ $0.07$ $1.29(0.90,1.85)$ $0.15$ $1.22(0.86,1.74)$ $0.25$ P for trend $0.02$ $0.03$ $0.05$	411 OR 1	1	1	· · · a		arp i d	
Q3 (0.21–0.43) 0.95(0.66,1.37) 0.79 0.95(0.64,1.39) 0.76 0.92(0.63,1.36) 0.66	P for trend		0.02		0.03		0.05
	Q4 (≥ 0.43)	1.36(0.97,1.91)	0.07	1.29(0.90,1.85)	0.15	1.22(0.86,1.74)	0.25
Q2 (0.09–0.20) 0.84(0.62,1.15) 0.28 0.83(0.59,1.16) 0.26 0.82(0.58,1.16) 0.23	Q3 (0.21–0.43)	0.95(0.66,1.37)	0.79	0.95(0.64,1.39)	0.76	0.92(0.63,1.36)	0.66
	Q2 (0.09–0.20)	0.84(0.62,1.15)	0.28	0.83(0.59,1.16)	0.26	0.82(0.58,1.16)	0.23

Abbreviations: *OR*, odds ratio; *CI*, confidence interval; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein.

\*Values are numerical values or weighted OR (95% CI).

Model 1 was adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI;

Model 2 was additionally adjusted for total cholesterol, and a history of diabetes and hypertension.

for occite teries only

1 2 3	
4	Supp
5 6	PIV
7	Q1 (<
8 9	Q2 (1
9 10	Q3 (2
11	Q4 (2
12	P for
13 14	SIRI
14 15	Q1 (<
16	Q2 (0
17	Q3 (1
18 10	Q4 (2
19 20	P for
21	SII
22	Q1 (<
23	Q2 (3
24 25	Q3 (5
26	Q4 (2
27	P for
28	NLR
29 30	Q1 (<
31	Q2 (1
32	Q3 (2
33	Q4 (2
34 35	P for
36	dNL
37	Q1 (<
38	Q2 (1
39 40	Q3 (1
41	Q4 (2
42	P for
43	MLR
44 45	Q1 (<
46	Q2 (0
47	Q3 (0
48	Q4 (2
49 50	P for
51	PLR
52	Q1 (<
53	Q2 (9
54 55	Q3 (1
56	Q4 (2
57	P for
58 50	CRP
59 60	Q1 (<

<b>PIV</b>						
O1 (< 191.50)						
Q1 (< 181.50)	1[Reference]		1[Reference]		1[Reference]	
Q2 (181.50–276.64)	0.95(0.66,1.36)	0.77	0.96(0.65,1.43)	0.84	0.98(0.65,1.50)	0.9
Q3 (276.65–421.83)	0.91(0.63,1.33)	0.63	0.88(0.58,1.34)	0.55	0.91(0.59,1.41)	0.6
Q4 (≥ 421.84)	1.34(1.02,1.77)	0.04	1.26(0.94,1.70)	0.12	1.25(0.91,1.71)	0.1
P for trend		0.01		0.06		0.1
SIRI						
Q1 (< 0.80)	1[Reference]		1[Reference]		1[Reference]	
Q2 (0.80–1.14)	0.84(0.61,1.15)	0.27	0.87(0.61,1.22)	0.39	0.86(0.60,1.22)	0.3
Q3 (1.15–1.65)	1.26(0.89,1.77)	0.18	1.20(0.80,1.80)	0.36	1.17(0.76,1.81)	0.4
Q4 (≥ 1.66)	1.58(1.16,2.16)	0.01	1.39(1.00,1.94)	0.05	1.30(0.92,1.84)	0.1
P for trend		< 0.01		0.01		0.0
SII						
Q1 (< 356.13)	1[Reference]		1[Reference]		1[Reference]	
Q2 (356.13–500.41)	0.78(0.57,1.07)	0.12	0.78(0.57,1.08)	0.12	0.82(0.60,1.12)	0.1
Q3 (500.42–702.31)	0.79(0.60,1.04)	0.10	0.85(0.63,1.14)	0.26	0.87(0.65,1.17)	0.3
Q4 (≥ 702.32)	1.03(0.78,1.38)	0.81	1.03(0.78,1.37)	0.81	1.04(0.78,1.40)	0.7
P for trend		0.39		0.36		0.3
NLR						
Q1 (< 1.56)	1[Reference]		1[Reference]		1[Reference]	
Q2 (1.56–2.08)	0.83(0.54,1.27)	0.37	0.95(0.61,1.47)	0.81	0.94(0.59,1.48)	0.7
Q3 (2.09–2.72)	1.20(0.86,1.66)	0.27	1.25(0.88,1.79)	0.20	1.23(0.86,1.76)	0.2
Q4 (≥ 2.73)	1.45(1.04,2.02)	0.03	1.32(0.94,1.87)	0.10	1.25(0.88,1.77)	0.2
P for trend		< 0.01		0.03		0.0
dNLR						
Q1 (< 1.13)	1[Reference]		1[Reference]		1[Reference]	
Q2 (1.13–1.44)	0.97(0.69,1.37)	0.85	1.03(0.70,1.51)	0.88	1.02(0.68,1.53)	0.9
Q3 (1.45–1.84)	1.04(0.75,1.44)	0.83	1.11(0.78,1.60)	0.53	1.11(0.78,1.59)	0.5
Q4 (≥ 1.85)	1.24(0.88,1.76)	0.22	1.18(0.82,1.70)	0.36	1.13(0.77,1.65)	0.5
P for trend		0.16		0.29		0.4
MLR						
Q1 (< 0.22)	1[Reference]		1[Reference]		1[Reference]	
Q2 (0.22–0.29)	0.88(0.62,1.24)	0.45	0.92(0.65,1.30)	0.62	0.92(0.65,1.30)	0.6
Q3 (0.30–0.37)	1.34(0.97,1.87)	0.08	1.37(1.00,1.87)	0.05	1.37(0.98,1.89)	0.0
Q4 (≥ 0.38)	1.83(1.32,2.53)	< 0.01	1.56(1.13,2.16)	0.01	1.49(1.07,2.08)	0.0
P for trend		< 0.01		< 0.01		< 0.
PLR						
Q1 (< 97.90)	1[Reference]		1[Reference]		1[Reference]	
Q2 (97.90–124.74)	0.79(0.56,1.11)	0.17	0.80(0.56,1.15)	0.21	0.84(0.57,1.24)	0.3
Q3 (124.75–159.41)	0.80(0.62,1.04)	0.09	0.94(0.74,1.20)	0.62	1.02(0.79,1.32)	0.8
Q4 (≥ 159.42)	1.01(0.70,1.45)	0.96	1.02(0.72,1.45)	0.91	1.08(0.74,1.56)	0.6
P for trend		0.74	. *	0.54		0.4
CRP, mg/dl						
Q1 (< 0.09)	1[Reference]		1[Reference]		1[Reference]	

Q2 (0.09–0.20)	1.13(0.80,1.61)	0.47	1.07(0.76,1.51)	0.70	1.04(0.75,1.46)	0.23
Q3 (0.21–0.43)	1.39(0.98,1.98)	0.06	1.18(0.81,1.71	0.38	1.16(0.80,1.69)	0.66
Q4 (≥ 0.43)	2.19(1.61,2.98)	< 0.01	1.67(1.14,2.43)	0.01	1.59(1.08,2.34)	0.02
P for trend		< 0.01		< 0.01		< 0.01
						-

Abbreviations: *OR*, odds ratio; *CI*, confidence interval; PIV, pan-immune-inflammation value; SIRI, system inflammation response index; SII, systemic immune-inflammation index; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein.


\*Values are numerical values or weighted OR (95% CI).

Model 1 was adjusted for age, race/ethnicity, education level, smoking status, alcohol use, and BMI;

Model 2 was additionally adjusted for total cholesterol, and a history of diabetes and hypertension.

to beet teries only


Page 31 of 34




166x156mm (300 x 300 DPI)

BMJ Open: first published as 10.1136/bmjopen-2023-080826 on 23 March 2024. Downloaded from http://bmjopen.bmj.com/ on June 10, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**BMJ** Open





		BMJ Open BMJ Open BMJ Open-2023	Page
	ST	ROBE 2007 (v4) Statement—Checklist of items that should be included in reports of creases - 🛱 ctional studies	
Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what vase found (b) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informative and balanced summary of what was done and what vase found (c) Provide in the abstract an informati	1
		៉ា ស៊ី ស៊ី ទុ (b) Provide in the abstract an informative and balanced summary of what was done and what væ្ឋាទូស្លែរាd	1-2
Introduction	•	aner ate	
Background/rationale	2		2-3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods		and	
Study design	4	Present key elements of study design early in the paper	3
Setting	5	Present key elements of study design early in the paper Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, by pw-up, and data collection	3-4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	3-4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers Give diagnostic criteria, if	3-4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (meas grentent). Describe comparability of assessment methods if there is more than one group	3-4
Bias	9	Describe any efforts to address potential sources of bias	3-4
Study size	10	Explain how the study size was arrived at	3
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which goungings were chosen and why	3-4
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	4-5
		(b) Describe any methods used to examine subgroups and interactions	4-5
		(c) Explain how missing data were addressed	4-5
		(d) If applicable, describe analytical methods taking account of sampling strategy	4-5
		(e) Describe any sensitivity analyses	4-5
Results		ů na na	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

34		BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open	
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, completing follow-up, and analysed	5
		(b) Give reasons for non-participation at each stage	5
		(c) Consider use of a flow diagram $d c b$	5
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information of the social social and information of the social social and information of the social social and potential confounders	5
		(b) Indicate number of participants with missing data for each variable of interest	5
Outcome data	15*	Report numbers of outcome events or summary measures	5-7
Main results	16	( <i>a</i> ) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision egg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	5-7
		interval). Make clear which confounders were adjusted for and why they were included	5-7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk for a meaningful and the stimates of relative risk into absolute risk into abso	5-7
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses $\overline{\mathbf{R}}$	7
Discussion			
Key results	18	Summarise key results with reference to study objectives	8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	8-10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	8-10
Generalisability	21	Discuss the generalisability (external validity) of the study results	8-10
Other information		arte	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, by original study on which the present article is based	11

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in controls in case-control studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published exan bles of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine  $\mathbb{F}rg/$ , Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.spidem.com/).

raphique

del